0001000228-21-000019 | 10-K | XBRL Viewer

Print Document View Excel Document

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 26, 2020	Feb. 08, 2021	Jun. 27, 2020
Cover Page
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-26
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 26, 2020
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN INC
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Public Float			$ 7,932,914,000
Entity Common Stock, Shares Outstanding		142,464,090
Entity Voluntary Filers	No
Documents Incorporated by Reference	Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the fiscal year (December 26, 2020) are incorporated by reference in Part III hereof.
ICFR Auditor Attestation Flag	true

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Current assets:
Cash and cash equivalents	$ 421,185	$ 106,097
Accounts receivable, net of reserves of $88,030 and $60,002	1,424,787	1,246,246
Inventories, net	1,512,499	1,428,799
Prepaid expenses and other	432,944	445,360
Total current assets	3,791,415	3,226,502
Property and equipment, net	342,004	329,645
Operating lease right-of-use assets, net	288,847	231,662
Goodwill	2,504,392	2,462,495
Other intangibles, net	479,429	572,878
Investments and other	366,445	327,919
Total assets	7,772,532	7,151,101
Current liabilities:
Accounts payable	1,005,655	880,266
Bank credit lines	73,366	23,975
Current maturities of long-term debt	109,836	109,849
Operating lease liabilities	64,716	65,349
Accrued expenses:
Payroll and related	295,329	265,206
Taxes	138,671	165,171
Other	595,529	528,553
Total current liabilities	2,283,102	2,038,369
Long-term debt	515,773	622,908
Deferred income taxes	30,065	64,989
Operating lease liabilities	238,727	176,267
Other liabilities	392,781	331,173
Total liabilities	3,460,448	3,233,706
Redeemable noncontrolling interests	327,699	287,258
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $.01 par value, 480,000,000 shares authorized, 142,462,571 outstanding on December 26, 2020 and 143,353,459 outstanding on December 28, 2019	1,425	1,434
Additional paid-in capital	0	47,768
Retained earnings	3,454,831	3,116,215
Accumulated other comprehensive loss	(108,084)	(167,373)
Total Henry Schein, Inc. stockholders' equity	3,348,172	2,998,044
Noncontrolling interests	636,213	632,093
Total stockholders' equity	3,984,385	3,630,137
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 7,772,532	$ 7,151,101

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Current assets:
Accounts receivable, reserves (in dollars)	$ 88,030	$ 60,002
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	142,462,571	143,353,459

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Income Statement [Abstract]
Net sales	$ 10,119,141	$ 9,985,803	$ 9,417,603
Cost of sales	7,304,798	6,894,917	6,506,856
Gross profit	2,814,343	3,090,886	2,910,747
Operating expenses:
Selling, general and administrative	2,246,947	2,357,920	2,217,273
Litigation settlements	0	0	38,488
Restructuring costs	32,093	14,705	54,367
Operating income	535,303	718,261	600,619
Other income (expense):
Interest income	9,842	15,757	15,491
Interest expense	(41,377)	(50,792)	(76,016)
Other, net	(3,873)	(2,919)	(3,258)
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests	499,895	680,307	536,836
Income taxes	(95,374)	(159,515)	(107,432)
Equity in earnings of affiliates	12,344	17,900	21,037
Net gain on sale of equity investments	1,572	186,769	0
Net income from continuing operations	418,437	725,461	450,441
Income (loss) from discontinued operations	986	(6,323)	111,685
Net income	419,423	719,138	562,126
Less: Net income attributable to noncontrolling interests	(15,629)	(24,770)	(19,724)
Less: Net (income) loss attributable to noncontrolling interests from discontinued operations	0	366	(6,521)
Net income attributable to Henry Schein, Inc.	403,794	694,734	535,881
Continuing Operations	402,808	700,691	430,717
Income (loss) from discontinued operations, net of tax	986	(5,957)	105,164
Net income attributable to Henry Schein, Inc.	$ 403,794	$ 694,734	$ 535,881
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 2.83	$ 4.74	$ 2.82
Diluted (in dollars per share)	2.81	4.69	2.80
Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	0.01	(0.04)	0.69
Diluted (in dollars per share)	0.01	(0.04)	0.68
Earnings per share attributable to Henry Schein, Inc. from continuing operations:
Basic (in dollars per share)	2.83	4.70	3.51
Diluted (in dollars per share)	$ 2.82	$ 4.65	$ 3.49
Weighted-average common shares outstanding:
Basic (in shares)	142,504	147,817	152,656
Diluted (in shares)	143,404	149,257	153,707

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 419,423	$ 719,138	$ 562,126
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	63,094	(4,070)	(136,356)
Unrealized gain (loss) from foreign currency hedging activities	(7,456)	(3,876)	626
Unrealized investment gain (loss)	(5)	12	(3)
Pension adjustment gain (loss)	143	(5,924)	3,033
Other comprehensive income (loss), net of tax	55,776	(13,858)	(132,700)
Comprehensive income	475,199	705,280	429,426
Comprehensive income attributable to noncontrolling interests:
Net income	(15,629)	(24,404)	(26,245)
Foreign currency translation (gain) loss	3,513	1,848	13,996
Comprehensive income attributable to noncontrolling interests	(12,116)	(22,556)	(12,249)
Comprehensive income (loss) attributable to Henry Schein, Inc.	$ 463,083	$ 682,724	$ 417,177

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Common Stock [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Retained Earnings [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]
Beginning Balance at Dec. 30, 2017	$ 2,824,410	$ 2,594	$ 1,537	$ 0	$ 0	$ 0	$ 2,940,029	$ 2,594	$ (130,067)	$ 0	$ 12,911	$ 0
Beginning Balance (in shares) at Dec. 30, 2017			153,690,146
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	540,278		$ 0		0		535,881		0		4,397
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(123,325)		0		0		0		(122,360)		(965)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	626		0		0		0		626		0
Unrealized investment gain (loss), net of tax impact	(3)		0		0		0		(3)		0
Pension adjustment gain (loss), net of tax impact	3,033		0		0		0		3,033		0
Dividends paid	(656)		0		0		0		0		(656)
Other adjustments	694		0		(19)		0		0		713
Purchase of noncontrolling interests	(214)		0		0		0		0		(214)
Change in fair value of redeemable securities	(148,919)		0		(148,919)		0		0		0
Initial noncontrolling interests and adjustments related to business acquisitions	564,270		0		0		0		0		564,270
Repurchase and retirement of common stock - Value	(200,000)		$ (25)		(36,206)		(163,769)		0		0
Repurchase and retirement of common stock - Shares			(2,518,387)
Stock issued upon exercise of stock options, Value	3,076		$ 1		3,075		0		0		0
Stock issued upon exercise of stock options, shares			153,516
Stock-based compensation expense - Value	36,240		$ 4		36,236		0		0		0
Stock-based compensation expense - Shares			340,794
Shares withheld for payroll taxes - Value	(18,143)		$ (3)		(18,140)		0		0		0
Shares withheld for payroll taxes - Shares			(267,772)
Settlement of stock-based compensation awards	(727)		$ 0		(727)		0		0		0
Settlement of stock-based compensation awards, shares			3,371
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	58,554		$ 0		58,554		0		0		0
Transfer of charges in excess of capital	0		0		106,146		(106,146)		0		0
Ending Balance at Dec. 29, 2018	3,541,788	(274)	$ 1,514	0	0	0	3,208,589	(274)	(248,771)	0	580,456	0
Ending Balance (in shares) at Dec. 29, 2018			151,401,668
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	704,666		$ 0		0		694,734		0		9,932
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(2,327)		0		0		0		(2,222)		(105)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(3,876)		0		0		0		(3,876)		0
Unrealized investment gain (loss), net of tax impact	12		0		0		0		12		0
Pension adjustment gain (loss), net of tax impact	(5,924)		0		0		0		(5,924)		0
Dividends paid	(535)		0		0		0		0		(535)
Other adjustments	(3)		0		(3)		0		0		0
Change in fair value of redeemable securities	7,300		0		7,300		0		0		0
Initial noncontrolling interests and adjustments related to business acquisitions	42,345		0		0		0		0		42,345
Adjustment for Animal Health Spin-off, Value	1		$ 1		0		0		0		0
Adjustment to stock for Spin-off transaction, Shares			87,629
Repurchase and retirement of common stock - Value	(525,000)		$ (82)		(79,785)		(445,133)		0		0
Repurchase and retirement of common stock - Shares			(8,173,912)
Stock issued upon exercise of stock options, Value	34		$ 0		34		0		0		0
Stock issued upon exercise of stock options, shares			2,526
Stock-based compensation expense - Value	45,245		$ 2		45,243		0		0		0
Stock-based compensation expense - Shares			215,408
Shares withheld for payroll taxes - Value	(10,845)		$ (1)		(10,844)		0		0		0
Shares withheld for payroll taxes - Shares			(179,860)
Settlement of stock-based compensation awards	160		$ 0		160		0		0		0
Settlement of stock-based compensation awards, shares			0
Share Sale related to Animal Health business	361,090		$ 0		361,090		0		0		0
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	(523,720)		0		(73,970)		(543,158)		93,408		0
Transfer of charges in excess of capital	0		0		(201,457)		201,457		0		0
Ending Balance at Dec. 28, 2019	$ 3,630,137	$ (412)	$ 1,434	$ 0	47,768	$ 0	3,116,215	$ (412)	(167,373)	$ 0	632,093	$ 0
Ending Balance (in shares) at Dec. 28, 2019	143,353,459		143,353,459
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	$ 406,060		$ 0		0		403,794		0		2,266
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	67,373		0		0		0		66,607		766
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(7,456)		0		0		0		(7,456)		0
Unrealized investment gain (loss), net of tax impact	(5)		0		0		0		(5)		0
Pension adjustment gain (loss), net of tax impact	143		0		0		0		143		0
Dividends paid	(1,086)		0		0		0		0		(1,086)
Purchase of noncontrolling interests	(2,298)		0		(1,597)		0		0		(701)
Change in fair value of redeemable securities	(32,842)		0		(32,842)		0		0		0
Adjustment for Animal Health Spin-off, Value	2,875		0		0		0		0		2,875
Repurchase and retirement of common stock - Value	$ (73,789)		$ (12)		(10,949)		(62,828)		0		0
Repurchase and retirement of common stock - Shares	(1,200,000)		(1,200,000)
Stock-based compensation expense - Value	$ 8,788		$ 5		8,783		0		0		0
Stock-based compensation expense - Shares	545,864		545,864
Shares withheld for payroll taxes - Value	$ (14,477)		$ (2)		(14,475)		0		0		0
Shares withheld for payroll taxes - Shares	(236,752)		(236,752)
Settlement of stock-based compensation awards	$ (275)		$ 0		(275)		0		0		0
Separation of Animal Health business	1,649		0		1,649		0		0		0
Transfer of charges in excess of capital	0		0		1,938		(1,938)		0		0
Ending Balance at Dec. 26, 2020	$ 3,984,385		$ 1,425		$ 0		$ 3,454,831		$ (108,084)		$ 636,213
Ending Balance (in shares) at Dec. 26, 2020	142,462,571		142,462,571

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Statement of Stockholders' Equity [Abstract]
Unrealized gain (loss) from foreign currency hedging activities, (tax benefit) tax	$ 2,768,000	$ 1,035,000	$ (396,000)
Unrealized investment gain (loss), tax benefit (tax)	(1,000)	2,000	0
Pension adjustment gain (loss), tax benefit (tax)	(676,000)	(1,806,000)	1,179,000
Stock issued upon exercise of stock options, tax benefit	0	0
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests			21,848,000
Foreign currency translation (gain) loss	4,279,000	2,335,000	11,330,000
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests	13,363,000	14,838,000
Foreign currency translation (gain) loss		2,335,000	$ 13,031,000
Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests	$ 13,363,000	(366,000)
Foreign currency translation (gain) loss		$ (592,000)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Cash flows from operating activities:
Net income	$ 419,423	$ 719,138	$ 562,126
Income (loss) from discontinued operations	986	(6,323)	111,685
Income from continuing operations	418,437	725,461	450,441
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	185,538	184,942	143,630
Impairment charge on intangible assets	20,275	0	0
Gain on sale of equity investments	(2,096)	(250,167)	0
Stock-based compensation expense	8,788	44,920	32,621
Provision for losses on trade and other accounts receivable	35,137	12,612	14,384
Benefit from deferred income taxes	(52,977)	(4,057)	(25,388)
Equity in earnings of affiliates	(12,344)	(17,900)	(21,037)
Distributions from equity affiliates	16,002	71,469	20,386
Changes in unrecognized tax benefits	(24,881)	1,941	(1,169)
Provision for (benefit from) transitional tax	0	0	(10,000)
Other	5,012	5,684	369
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(189,349)	(72,689)	(127,201)
Inventories	(31,817)	14,702	(41,042)
Other current assets	(6,479)	(57,291)	(165,645)
Accounts payable and accrued expenses	224,273	160,851	180,606
Net cash provided by operating activities from continuing operations	593,519	820,478	450,955
Net cash provided by (used in) operating activities from discontinued operations	5,391	(166,391)	233,751
Net cash provided by operating activities	598,910	654,087	684,706
Cash flows from investing activities:
Purchases of fixed assets	(48,829)	(76,219)	(71,283)
Payments related to equity investments and business acquisitions, net of cash acquired	(60,173)	(655,879)	(53,240)
Proceeds from sale of equity investment	14,020	307,251	1,000
Repayments from (borrowings for) loan to affiliate	(1,243)	16,713	(25,700)
Other	(18,794)	(14,175)	(15,101)
Net cash used in investing activities from continuing operations	(115,019)	(422,309)	(164,324)
Net cash used in investing activities from discontinued operations	0	(2,064)	(28,630)
Net cash used in investing activities	(115,019)	(424,373)	(192,954)
Cash flows from financing activities:
Net change in bank borrowings	45,082	(927,912)	210,741
Proceeds from issuance of long-term debt	501,421	741	115,000
Principal payments for long-term debt	(611,216)	(260,944)	(24,735)
Debt issuance costs	(3,879)	(391)	(501)
Debt extinguishment costs	(401)	0	0
Proceeds from issuance of stock upon exercise of stock options	0	34	3,076
Payments for repurchases of common stock	(73,789)	(525,000)	(200,000)
Payments for taxes related to shares withheld for employee taxes	(14,299)	(10,814)	(18,023)
Distribution received related to Animal Health Spin-off	0	1,120,000	0
Proceeds related to Animal Health Share Sale	0	361,090	0
Proceeds from (distributions to) noncontrolling stockholders	(7,886)	51,498	(7,351)
Acquisitions of noncontrolling interests in subsidiaries	(19,538)	(2,358)	(287,635)
(Payments) or proceeds to from Henry Schein Animal Health Business	2,711	(169,295)	(192,745)
Net cash used in financing activities from continuing operations	(181,794)	(363,351)	(402,173)
Net cash provided by (used in) financing activities from discontinued operations	(5,391)	147,371	(201,603)
Net cash used in financing activities	(187,185)	(215,980)	(603,776)
Effect of exchange rate changes on cash and cash equivalents-continuing operations	18,382	14,394	14,425
Effect of exchange rate changes on cash and cash equivalents-discontinued operations	0	(2,240)	3,150
Net change in cash and cash equivalents from continuing operations	315,088	49,212	(101,117)
Net change in cash and cash equivalents from discontinued operations	0	(23,324)	6,668
Net change in cash and cash equivalents	315,088	25,888	(94,449)
Cash and cash equivalents, beginning of period	106,097	56,885	158,002
Cash and cash equivalents, end of period	$ 421,185	$ 106,097	$ 56,885

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 26, 2020
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 1 –Significant Accounting Policies Nature of Operations We distribute health care products and services primarily to office-based health care practitioners with operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom. Principles of Consolidation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements. For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At December 26, 2020 and December 28, 2019, trade accounts receivable that can only be used to settle obligations of this VIE were $ 0.0 million and $ 127 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were $ 0.0 million and $ 100 million, respectively. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand increased in the second half of the year resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products. Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the latter half of the year, dental and medical practices began to re-open worldwide, and continued to do so during the remainder of the year. However, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time. Fiscal Year We report our results of operations and cash flows on a 52 - 53 week basis ending on the last Saturday of December. The years ended December 26, 2020, December 28, 2019 and December 29, 2018 consisted of 52 weeks. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following: • identify the contract(s) with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when, or as, the entity satisfies a performance obligation. We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment. Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with Accounting Standards Codification (“ASC”) 460 “Guarantees”. Revenue derived from the sale of software products is recognized when products are shipped to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract. Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations, which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. There are no cases where revenue is deferred due to a lack of a standalone selling price. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Contract Balances Contract balances represent amounts presented in our consolidated balance sheet when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Accounts Receivable Accounts receivable are generally recognized when health care distribution and technology and value-added services revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. Contract Assets Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in Investments and other within our consolidated balance sheets. Current and non-current contract asset balances as of December 26, 2020 and December 28, 2019 were not material. Contract Liabilities Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in Accrued expenses: Other and the non-current contract liabilities are included in Other liabilities within our consolidated balance sheets. At December 28, 2019, the current portion of contract liabilities of $ 70.8 million was reported in Accrued expenses: Other, and $ 6.2 million related to non-current contract liabilities were reported in Other liabilities. During the year ended December 26, 2020, we recognized substantially all of the current contract liability amounts that were previously deferred at December 28, 2019. At December 26, 2020, the current and non-current portion of contract liabilities were $ 71.5 million and $ 8.2 million, respectively. Deferred Commissions Sales commissions earned by our sales force that relate to long term arrangements are capitalized as costs to obtain a contract when the costs incurred are incremental and are expected to be recovered. Deferred sales commissions are amortized over the estimated customer relationship period. We apply the practical expedient related to the capitalization of incremental costs of obtaining a contract, and recognize such costs as an expense when incurred if the amortization period of the assets that we would have recognized is one year or less. Our deferred commission balances as of December 26, 2020 and December 28, 2019 were not material. Sales Returns Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any products that we expect to be returned. Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory. Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $ 1.3 million and $ 29.5 million, primarily related to payments for inventory, were classified as accounts payable as of December 26, 2020 and December 28, 2019. Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $ 79.2 million, $ 73.8 million and $ 70.6 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $ 30.8 million, $ 25.2 million and $ 12.9 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized. Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80 % or greater owned U.S. subsidiaries. Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings. Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item. Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings. Total return swaps are entered into for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. This swap is expected to be renewed on an annual basis. Acquisitions We account for business acquisitions and combinations under the acquisition method of accounting, where the net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rates; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations. For the years ended December 26, 2020, December 28, 2019 and December 29, 2018, there were no material adjustments recorded in our consolidated statement of income relating to changes in subsequent adjustments or estimated contingent purchase price liabilities. Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. Noncontrolling Interests Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests. Goodwill Goodwill is not amortized, but is subject to impairment analysis annually or more frequently if there is a triggering event or if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Such impairment analyses for goodwill requires a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: global dental; global medical; and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. On December 29, 2019 we adopted Account Standards Update (“ASU”) 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminated step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. We perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. Goodwill as of December 26, 2019 and December 29, 2018 were tested under the prior standard. For the year ended December 26, 2020 we tested goodwill for impairment, on the first day of the fourth quarter, using a quantitative analysis comparing the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Conversely, impairment loss would be equivalent to the excess of a reporting unit’s carrying value over its fair value limited to the total amount of goodwill allocated to that reporting unit. For the years ended December 26, 2019 and December 29, 2018 we tested goodwill for impairment on the first day of the fourth quarter, using a quantitative analysis which consisted of a two-step approach. The first step of our quantitative analysis consisted of a comparison of the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If step one resulted in the carrying value of the reporting unit exceeding the fair value of such reporting unit, we would have then proceeded to step two which would have required us to calculate the amount of impairment loss, if any, that we would have recorded for such reporting unit. The calculation of the impairment loss in step two would have been equivalent to the reporting unit’s carrying value of goodwill less the implied fair value of such goodwill. Our use of a discounted cash flow methodology includes estimates of future revenue based upon budget projections and growth rates which take into account estimated inflation rates. We also develop estimates for future levels of gross and operating profits and projected capital expenditures. Our methodology also includes the use of estimated discount rates based upon industry and competitor analysis as well as other factors. The estimates that we use in our discounted cash flow methodology involve many assumptions by management that are based upon future growth projections. Some factors we consider important that could trigger an interim impairment review include: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or significant negative industry or economic trends. If we determine through the impairment review process that goodwill is impaired, we record an impairment charge in our consolidated statements of income. For the years ended December 28, 2019 and December 29, 2018, the results of our goodwill impairment analysis did no t result in any impairments. Long-Lived Assets Long-lived assets, other than goodwill and other definite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. During the year ended December 26, 2020, we recorded total impairment charges on intangible assets of approximately $ 20.3 million, nearly all of which was recorded in our technology and value-added services segment. Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $ 71.7 million, $ 72.3 million and $ 69.6 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss). Leases On December 30, 2018, we adopted ASC Topic 842, Leases, using a modified retrospective approach, whereby we continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption. We elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Information related to leases as of December 28, 2019 is presented under Topic 842, while prior period amounts are not adjusted and continue to be reported under legacy guidance in ASC Topic 840, Leases. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. Adoption of the new standard resulted in the recording of additional net operating lease assets of $ 259.9 million and operating lease liabilities of $ 267.3 million, and a decrease of $ 1.1 million and $ 8.5 million in prepaid rent and deferred rent liabilities, respectively. The standard did not materially impact our consolidated net income and had no impact on cash flows. We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases and finance leases are included in “Selling, general and administrative” and “Interest expense”, respectively within our Consolidated Statement of Income. Leases with a lease term of 12 months or less are not capitalized. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price. Accounting Pronouncements Adopted On December 29, 2019, we adopted ASU No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 requires us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. Our adoption of ASU 2017-04 did not have a material impact on our consolidated financial statements. On December 29, 2019, we adopted ASU No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. We adopted Topic 326 using the modified- retrospective method and recorded an immaterial cumulative-effect adjustment to the opening balance of retained earnings. Based upon the level and makeup of our financial asset portfolio, including accounts receivable, past loan loss activity and current known activity regarding our outstanding loans, the adoption of this ASU resulted in a decrease of $ 0.4 million to retained earnings. Recently Issued Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020- 06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings- per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

Discontinued Operations	12 Months Ended
Discontinued Operations	Dec. 26, 2020
Discontinued Operations [Abstract]
Discontinued Operations	Note 2 – Discontinued Operations Animal Health Spin-off On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $ 1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $ 361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63 % of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37 % of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market. In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement, which ended in December 2020, with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health Business are presented as discontinued operations and have been excluded from continuing operations and segment results for all periods presented. The accompanying Notes to the Consolidated Financial Statements have been revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at December 26, 2020. Summarized financial information for our discontinued operations is as follows: Years Ended December 26, December 28, December 29, 2020 2019 2018 Net sales $ - $ 319,522 $ 3,784,392 Cost of goods sold - 260,097 3,100,055 Gross profit - 59,425 684,337 Selling, general and administrative 2,347 68,919 531,905 Operating income (loss) (2,347) (9,494) 152,432 Income tax expense (benefit) (3,333) (2,181) 48,060 Income (loss) from discontinued operations 986 (6,323) 111,685 Net (income) loss attributable to noncontrolling interests - 366 (6,521) Net income (loss) from discontinued operations attributable to Henry Schein, Inc. 986 (5,957) 105,164 The operating loss from discontinued operations for the year ended December 26, 2020 was primarily attributable to costs directly related to the Animal Health Spin-off. The net income from discontinued operations for the year ended December 26, 2020 was primarily attributable to a reduction in a liability for tax indemnification and a tax refund received during 2020 by a holding company previously part of our Animal Health legal structure and other favorable tax resolutions. The financial information above, for the year ended December 28, 2019, represents activity of the discontinued operations during year-to-date through the Distribution Date. The loss from discontinued operations for the year ended December 28, 2019 was primarily attributable to the inclusion of the transaction costs directly related to the Animal Health Spin-off. The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019. February 7, 2019 Cash and cash equivalents $ 6,815 Accounts receivable, net 432,812 Inventories, net 536,637 Prepaid expenses and other 120,546 Total current assets of discontinued operations 1,096,810 Property and equipment, net 69,790 Operating lease right-of-use asset, net 57,012 Goodwill 742,931 Other intangibles, net 205,793 Investments and other 120,518 Total long-term assets of discontinued operations 1,196,044 Total assets of discontinued operations $ 2,292,854 Accounts payable $ 316,162 Current maturities of long-term debt 657 Operating lease liabilities 18,951 Accrued expenses: Payroll and related 36,847 Taxes 24,060 Other 80,400 Total current liabilities of discontinued operations 477,077 Long-term debt 1,176,105 Deferred income taxes 17,019 Operating lease liabilities 38,668 Other liabilities 29,209 Total long-term liabilities of discontinued operations 1,261,001 Total liabilities of discontinued operations $ 1,738,078 Redeemable noncontrolling interests $ 28,270

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 26, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 3 – Property and Equipment, Net Property and equipment, including related estimated useful lives, consisted of the following: December 26, December 28, 2020 2019 Land $ 20,297 $ 18,030 Buildings and permanent improvements 145,160 121,823 Leasehold improvements 107,753 104,089 Machinery and warehouse equipment 142,437 124,640 Furniture, fixtures and other 108,041 99,083 Computer equipment and software 344,494 330,926 868,182 798,591 Less accumulated depreciation (526,178) (468,946) Property and equipment, net $ 342,004 $ 329,645 Estimated Useful Lives (in years) Buildings and permanent improvements 40 Machinery and warehouse equipment 5 - 10 Furniture, fixtures and other 3 - 10 Computer equipment and software 3 - 10 Property and equipment related depreciation expense for the years ended December 26, 2020, December 28, 2019 and December 29, 2018 was $ 64.3 million, $ 64.4 million and $ 58.1 million.

Goodwill and Other Intangibles, Net	12 Months Ended
Goodwill and Other Intangibles, Net	Dec. 26, 2020
Goodwill and other Intangibles, Net Disclosure [Abstract]
Goodwill and Other Intangibles, Net	Note 4 – Goodwill and Other Intangibles, Net The changes in the carrying amount of goodwill for the years ended December 26, 2020 and December 28, 2019 were as follows: Health Care Distribution Technology and Value-Added Services Total Balance as of December 29, 2018 $ 1,433,412 $ 647,617 $ 2,081,029 Adjustments to goodwill: Acquisitions 50,276 338,352 388,628 Foreign currency translation (6,969) (193) (7,162) Balance as of December 28, 2019 1,476,719 985,776 2,462,495 Adjustments to goodwill: Acquisitions 14,230 12,101 26,331 Foreign currency translation 9,888 5,678 15,566 Balance as of December 26, 2020 $ 1,500,837 $ 1,003,555 $ 2,504,392 Other intangible assets consisted of the following: December 26, 2020 December 28, 2019 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Non-compete agreements $ 30,993 $ (11,480) $ 19,513 $ 34,553 $ (9,327) $ 25,226 Trademarks / trade names - definite lived 95,382 (50,893) 44,489 99,314 (44,134) 55,180 Customer relationships and lists 652,605 (283,469) 369,136 715,630 (274,330) 441,300 Product Development 94,216 (54,451) 39,765 85,211 (42,326) 42,885 Other 14,188 (7,662) 6,526 26,237 (17,950) 8,287 Total $ 887,384 $ (407,955) $ 479,429 $ 960,945 $ (388,067) $ 572,878 Non-compete agreements represent amounts paid primarily to key employees and prior owners of acquired businesses, as well as certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete period, which generally commences upon termination of employment or separation from us. The weighted-average non-compete period for agreements currently being amortized was approximately 5.1 years as of December 26, 2020. Trademarks, trade names, customer lists and customer relationships were established through business acquisitions. Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-average period of approximately 8.1 years as of December 26, 2020. Customer relationships and customer lists are definite-lived intangible assets that are amortized on a straight-line basis over a weighted-average period of approximately 10.0 years as of December 26, 2020. Product development is a definite-lived intangible asset that is amortized on a straight-line basis over a weighted-average period of approximately 8.5 years as of December 26, 2020. Amortization expense related to definite-lived intangible assets for the years ended December 26, 2020, December 28, 2019 and December 29, 2018 was $ 105.9 million, $ 108.3 million and $ 75.3 million. During the year ended December 26, 2020, we recorded total impairment charges on intangible assets of approximately $ 20.3 million. The annual amortization expense expected to be recorded for existing intangibles assets for the years 2021 through 2025 is $ 99.3 million, $ 85.5 million, $ 78.0 million, $ 54.8 million and $ 43.2 million.

Investments and Other	12 Months Ended
Investments and Other	Dec. 26, 2020
Investments And Other [Abstract]
Investments and Other	Note 5 – Investments and Other Investments and other consisted of the following: December 26, December 28, 2020 2019 Investment in unconsolidated affiliates $ 169,382 $ 164,659 Non-current deferred foreign, state and local income taxes 42,594 23,625 Notes receivable (1) 34,760 43,544 Capitalized costs for internally generated software for resale 47,650 42,445 Security deposits 1,752 534 Acquisition-related indemnification 49,401 38,464 Other long-term assets 20,906 14,648 Total $ 366,445 $ 327,919 (1) Long-term notes receivable carry interest rates ranging from 1 .0% to 14 .0% and are due in varying installments through September 30, 2027 . Amortization expense related to other long-term assets for the years ended December 26, 2020, December 28, 2019 and December 29, 2018 was $ 15.3 million, $ 12.3 million and $ 10.2 million.

Debt	12 Months Ended
Debt	Dec. 26, 2020
Debt [Abstract]
Debt	Note 6 – Debt Bank Credit Lines Bank credit lines consisted of the following: December 26, December 28, 2020 2019 Revolving credit agreement $ - $ - Other short-term bank credit lines 73,366 23,975 Total $ 73,366 $ 23,975 Revolving Credit Agreement On April 18, 2017 , we entered into a $ 750 million revolving credit agreement (the “Credit Agreement”), which matures in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect the LIBOR rate to be discontinued at some point during 2021, which will require an amendment to our debt agreements to reflect a new reference rate. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement also requires, among other things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of December 26, 2020 and December 28, 2019, we had no borrowings on this revolving credit facility. As of December 26, 2020 and December 28, 2019, there were $ 9.5 million and $ 9.6 million of letters of credit, respectively, provided to third parties under the credit facility. On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021. 364-Day Credit Agreement On April 17, 2020 , we entered into a new $ 700 million 364 -day credit agreement, with JPMorgan Chase Bank, N.A. and U.S. Bank National Association as joint lead arrangers and joint bookrunners. This facility matures on April 16, 2021 . As of December 26, 2020, we had no borrowings under this credit facility. We have the ability to borrow up to an additional $ 200 million, from the original facility amount of $ 700 million, under this credit facility on a revolving basis as needed, subject to the terms and conditions of the credit agreement. The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At December 26, 2020, the interest rate on this facility was 2.50%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness . Under the terms of this agreement, we are prohibited from repurchasing our common stock until we report our financial results for the second quarter of 2021. Other Short-Term Credit Lines As of December 26, 2020 and December 28, 2019, we had various other short-term bank credit lines available, of which $ 73.4 million and $ 24.0 million, respectively, were outstanding. At December 26, 2020 and December 28, 2019, borrowings under all of these credit lines had a weighted average interest rate of 4.14 % and 3.45 %, respectively. Long-term debt Long-term debt consisted of the following: December 26, December 28, 2020 2019 Private placement facilities $ 613,498 $ 621,274 U.S. trade accounts receivable securitization - 100,000 Note payable due in 2025 with an interest rate of 3.1% at December 26, 2020 1,554 - Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 2.62% to 4.27% at December 26, 2020 and ranging from 2.56% to 10.5% at December 28, 2019 4,596 6,089 Finance lease obligations (see Note 7) 5,961 5,394 Total 625,609 732,757 Less current maturities (109,836) (109,849) Total long-term debt $ 515,773 $ 622,908 Private Placement Facilities Our private placement facilities, with three insurance companies, have a total facility amount of $ 1 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through June 23, 2023 . The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above private placement facilities to, among other things, (i) permit the consummation of the Animal Health Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. On June 23, 2020, we amended the private placement facilities to, among other things, (i) temporarily modify the financial covenant from being based on total leverage ratio to net leverage ratio until March 31, 2021, (ii) increase the maximum maintenance leverage ratio through March 31, 2021, but with a 1.00% interest rate increase on the outstanding notes if the net leverage ratio exceeds 3.0x, which will remain in effect until we deliver financials for a four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conforming to the Credit Agreement, dated as of April 18, 2017, as amended. The components of our private placement facility borrowings as of December 26, 2020 are presented in the following table (in thousands): Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date January 20, 2012 (1) $ 14,286 3.09 % January 20, 2022 January 20, 2012 50,000 3.45 January 20, 2024 December 24, 2012 50,000 3.00 December 24, 2024 June 2, 2014 100,000 3.19 June 2, 2021 June 16, 2017 100,000 3.42 June 16, 2027 September 15, 2017 100,000 3.52 September 15, 2029 January 2, 2018 100,000 3.32 January 2, 2028 September 2, 2020 (2) 100,000 2.35 September 2, 2030 Less: Deferred debt issuance costs (788) $ 613,498 (1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016. (2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030. U.S. Trade Accounts Receivable Securitization We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . Our current facility, which has a purchase limit of $ 350 million, was scheduled to expire on April 29, 2022 . On June 22, 2020, the expiration date for this facility was extended to June 12, 2023 and was amended to adjust certain covenant levels for 2020. As of December 26, 2020 and December 28, 2019, the borrowings outstanding under this securitization facility were $ 0.0 million and $ 100 million, respectively. At December 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22 % plus 0.95 %, for a combined rate of 1.17 %. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 1.90 % plus 0.75 %, for a combined rate of 2.65 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization. As of December 26, 2020, the aggregate amounts of long-term debt, including finance lease obligations and net of deferred debt issuance costs of $ 0.8 million, maturing in each of the next five years and thereafter are as follows: 2021 $ 109,836 2022 11,607 2023 1,916 2024 100,303 2025 1,839 Thereafter 400,108 Total $ 625,609

Leases	12 Months Ended
Leases	Dec. 26, 2020
Leases [Abstract]
Leases	Note 7 – Leases Leases We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment. Our leases have remaining terms of less than one year to approximately 16 years , some of which may include options to extend the leases for up to 10 years . The components of lease expense were as follows: Years Ended December 26, December 28, 2020 2019 Operating lease cost: (1) (2) $ 86,800 $ 88,246 Finance lease cost: Amortization of right-of-use assets 2,209 1,154 Interest on lease liabilities 115 131 Total finance lease cost $ 2,324 $ 1,285 (1) Includes variable lease expenses. (2) Operating lease cost for each of the years ended December 26, 2020, and December 28, 2019, includes amortization of right-of-use assets of $ 0.6 million, related to facility leases recorded in “Restructuring costs” within our consolidated statements of income. Supplemental balance sheet information related to leases is as follows: Years Ended December 26, December 28, 2020 2019 Operating Leases: Operating lease right-of-use assets $ 288,847 $ 231,662 Current operating lease liabilities 64,716 65,349 Non-current operating lease liabilities 238,727 176,267 Total operating lease liabilities $ 303,443 $ 241,616 Finance Leases: Property and equipment, at cost $ 10,683 $ 10,268 Accumulated depreciation (4,277) (4,581) Property and equipment, net of accumulated depreciation $ 6,406 $ 5,687 Current maturities of long-term debt $ 2,420 $ 1,736 Long-term debt 3,541 3,658 Total finance lease liabilities $ 5,961 $ 5,394 Weighted Average Remaining Lease Term in Years: Operating leases 7.5 5.5 Finance leases 4.3 5.0 Weighted Average Discount Rate: Operating leases 2.8 % 3.4 % Finance leases 1.9 % 2.2 % Supplemental cash flow information related to leases is as follows: Years Ended December 26, December 28, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 76,985 79,699 Operating cash flows for finance leases 101 99 Financing cash flows for finance leases 2,148 1,413 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 120,148 297,800 Finance leases 2,947 2,940 Maturities of lease liabilities are as follows: December 26, 2020 Operating Finance Leases Leases 2021 $ 71,801 $ 2,503 2022 58,049 1,542 2023 40,670 596 2024 28,899 327 2025 26,147 305 Thereafter 110,228 920 Total future lease payments 335,794 6,193 Less imputed interest (32,351) (232) Total $ 303,443 $ 5,961 As of December 26, 2020, we have additional operating leases with total lease payments of $ 13.5 million for buildings and vehicles that have not yet commenced. These operating leases will commence subsequent to December 26, 2020, with lease terms of two years to 10 years .

Redeemable Noncontrolling Interests	12 Months Ended
Redeemable Noncontrolling Interests	Dec. 26, 2020
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 8 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the Redeemable noncontrolling interests for the years ended December 26, 2020, December 28, 2019 and December 29, 2018 are presented in the following table: December 26, December 28, December 29, 2020 2019 2018 Balance, beginning of period $ 287,258 $ 219,724 $ 465,585 Decrease in redeemable noncontrolling interests due to redemptions (17,241) (2,270) (287,767) Increase in redeemable noncontrolling interests due to business acquisitions 28,387 74,865 4,655 Net income attributable to redeemable noncontrolling interests 13,363 14,838 15,327 Dividends declared (12,631) (10,264) (8,206) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (4,279) (2,335) (11,330) Change in fair value of redeemable securities 32,842 (7,300) 41,460 Balance, end of period $ 327,699 $ 287,258 $ 219,724

Comprehensive Income	12 Months Ended
Comprehensive Income	Dec. 26, 2020
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Comprehensive Income	Note 9 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: December 26, December 28, December 29, 2020 2019 2018 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (24,617) $ (20,338) $ (18,595) Attributable to noncontrolling interests: Foreign currency translation adjustment $ 235 $ (531) $ (426) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (76,565) $ (143,172) $ (234,799) Unrealized loss from foreign currency hedging activities (11,488) (4,032) (156) Unrealized investment gain (loss) 1 6 (6) Pension adjustment loss (20,032) (20,175) (13,810) Accumulated other comprehensive loss $ (108,084) $ (167,373) $ (248,771) Total Accumulated other comprehensive loss $ (132,466) $ (188,242) $ (267,792) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: December 26, December 28, December 29, 2020 2019 2018 Net income $ 419,423 $ 719,138 $ 562,126 Foreign currency translation gain (loss) 63,094 (4,070) (136,356) Tax effect - - - Foreign currency translation gain (loss) 63,094 (4,070) (136,356) Unrealized gain (loss) from foreign currency hedging activities (10,224) (4,911) 1,022 Tax effect 2,768 1,035 (396) Unrealized gain (loss) from foreign currency hedging activities (7,456) (3,876) 626 Unrealized investment gain (loss) (6) 14 (3) Tax effect 1 (2) - Unrealized investment gain (loss) (5) 12 (3) Pension adjustment gain (loss) (533) (7,730) 4,212 Tax effect 676 1,806 (1,179) Pension adjustment gain (loss) 143 (5,924) 3,033 Comprehensive income $ 475,199 $ 705,280 $ 429,426 Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the years ended December 26, 2020, December 28, 2019 and December 29, 2018 was impacted by changes in foreign currency exchange rates of the Euro, Brazilian Real, British Pound and Australian Dollar The following table summarizes our total comprehensive income, net of applicable taxes as follows: December 26, December 28, December 29, 2020 2019 2018 Comprehensive income attributable to Henry Schein, Inc. $ 463,083 $ 682,724 $ 417,177 Comprehensive income attributable to noncontrolling interests 3,032 9,827 3,432 Comprehensive income attributable to Redeemable noncontrolling interests 9,084 12,729 8,817 Comprehensive income $ 475,199 $ 705,280 $ 429,426

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 26, 2020
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 10 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The hierarchy for determining that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy and as of December 26, 2020 and December 28, 2019 was estimated at $ 699.0 million and $ 756.7 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges; and a total return swap for the purpose of economically hedging our unfunded non-qualified SERP and our DCP. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 26, 2020 and December 28, 2019: December 26, 2020 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,868 $ - $ 1,868 Total return swaps - 1,565 - 1,565 Total assets $ - $ 3,433 $ - $ 3,433 Liabilities: Derivative contracts $ - $ 11,765 $ - $ 11,765 Total liabilities $ - $ 11,765 $ - $ 11,765 Redeemable noncontrolling interests $ - $ - $ 327,699 $ 327,699 December 28, 2019 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 567 $ - $ 567 Total assets $ - $ 567 $ - $ 567 Liabilities: Derivative contracts $ - $ 5,795 $ - $ 5,795 Total liabilities $ - $ 5,795 $ - $ 5,795 Redeemable noncontrolling interests $ - $ - $ 287,258 $ 287,258

Business Acquisitions and Divestitures	12 Months Ended
Business Acquisitions and Divestitures	Dec. 26, 2020
Business Acquisitions and Divestitures [Abstract]
Business Acquisitions and Divestitures	Note 11 – Business Acquisitions and Divestitures The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates. We completed acquisitions during the year ended December 26, 2020, which were immaterial to our financial statements individually. In the aggregate, these transactions resulted in consideration of $ 57.8 million in 2020 related to business combinations, for net assets amounting to $ 32.8 million. As of December 26, 2020, we had recorded $ 36.9 million of identifiable intangibles, $ 23.9 million of goodwill and $ 26.4 million of non-controlling interest, related to these acquisitions. Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition, none of which are material. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the years ended December 26, 2020, December 28, 2019 and December 29, 2018, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities. Divestitures of Investments During the fourth quarter of 2019, we sold an equity investment in Hu-Friedy Mfg. Co., LLC, a manufacturer of dental instruments and infection prevention solutions. Our investment was non-controlling, we were not involved in running the business and had no representation on the board of directors. During the fourth quarter of 2019, we also sold certain other equity investments. In the aggregate, the sales of these investments resulted in a pre-tax gain of approximately $ 250.2 million, net of taxes of approximately $ 63.4 million. In the fourth quarter of 2020 we received contingent proceeds of $ 2.1 million from the 2019 sale of Hu-Friedy resulting in the recognition of an additional after-tax gain of $1.6 million. For the years ended December 28, 2019 and December 29, 2018, we recognized approximately $ 6.0 million and $ 10.4 million of equity in earnings from these affiliates. Acquisition Costs During the years ended December 26, 2020, December 28, 2019, and December 29, 2018 we incurred $ 5.9 million, $ 4.5 million and $ 7.3 million in acquisition costs from continuing operations. In February 2019, we completed the Animal Health Spin-off. During the years ended December 26, 2020, December 28, 2019, and December 29, 2018, we incurred $ 0.1 million, $ 23.6 million and $ 38.9 million in transaction costs associated with this transaction. We do not expect to incur additional spin-off related transaction costs after December 26, 2020. All transaction costs related to the Animal Health Spin-off have been included in results from discontinued operations.

Plans of Restructuring	12 Months Ended
Plans of Restructuring	Dec. 26, 2020
Restructuring and Related Activities [Abstract]
Plans of Restructuring	Note 12 – Plans of Restructuring On July 9, 2018, we committed to an initiative to rationalize our operations and provide expense efficiencies. These actions allowed us to execute on our plan to reduce our cost structure and fund new initiatives to drive growth under our 2018 to 2020 strategic plan. This initiative resulted in the elimination of approximately 4 % of our workforce and the closing of certain facilities. On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities were originally expected to be completed by the end of 2020. As a result of the business environment brought on by the COVID-19 pandemic, we are continuing our restructuring activities into 2021. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. During the years ended December 26, 2020, December 28, 2019, and December 29, 2018 we recorded restructuring charges of $ 32.1 million, $ 14.7 million and $ 54.4 million, respectively. The costs associated with these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income. The following table shows the amounts expensed and paid for restructuring costs that were incurred during our 2020, 2019 and 2018 fiscal years and the remaining accrued balance of restructuring costs as of December 26, 2020, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet: Facility Severance Closing Costs Costs Other Total Balance, December 30, 2017 $ 3,087 $ 1,315 $ 24 $ 4,426 Provision 50,197 3,153 1,017 54,367 Payments and other adjustments (23,320) (2,865) (883) (27,068) Balance, December 29, 2018 $ 29,964 $ 1,603 $ 158 $ 31,725 Provision 13,741 937 27 14,705 Payments and other adjustments (30,794) (1,714) (112) (32,620) Balance, December 28, 2019 $ 12,911 $ 826 $ 73 $ 13,810 Provision 25,855 5,878 360 32,093 Payments and other adjustments (26,152) (6,309) (329) (32,790) Balance, December 26, 2020 $ 12,614 $ 395 $ 104 $ 13,113 The following table shows, by reportable segment, the amounts expensed and paid for restructuring costs that were incurred during our 2020, 2019 and 2018 fiscal years and the remaining accrued balance of restructuring costs as of December 26, 2020: Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2017 $ 4,426 $ - $ 4,426 Provision 50,824 3,543 54,367 Payments and other adjustments (24,959) (2,109) (27,068) Balance, December 29, 2018 $ 30,291 $ 1,434 $ 31,725 Provision 13,935 770 14,705 Payments and other adjustments (30,853) (1,767) (32,620) Balance, December 28, 2019 $ 13,373 $ 437 $ 13,810 Provision 30,935 1,158 32,093 Payments and other adjustments (31,484) (1,306) (32,790) Balance, December 26, 2020 $ 12,824 $ 289 $ 13,113

Earnings Per Share	12 Months Ended
Earnings Per Share	Dec. 26, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Note 13 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Years Ended December 26, December 28, December 29, 2020 2019 2018 Basic 142,504 147,817 152,656 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 900 1,440 1,051 Diluted 143,404 149,257 153,707

Income Taxes	12 Months Ended
Income Taxes	Dec. 26, 2020
Income Taxes [Abstract]
Income Taxes	Note 14 – Income Taxes Income before taxes and equity in earnings of affiliates was as follows: Years ended December 26, December 28, December 29, 2020 2019 2018 Domestic $ 430,838 $ 507,003 $ 405,289 Foreign 69,057 173,304 131,547 Total $ 499,895 $ 680,307 $ 536,836 The provisions for income taxes were as follows: Years ended December 26, December 28, December 29, 2020 2019 2018 Current income tax expense: U.S. Federal $ 82,912 $ 93,418 $ 71,854 State and local 24,640 28,150 22,533 Foreign 40,799 42,004 38,433 Total current 148,351 163,572 132,820 Deferred income tax expense (benefit): U.S. Federal (18,032) 5,633 206 State and local (4,889) 1,597 (1,622) Foreign (30,056) (11,287) (23,972) Total deferred (52,977) (4,057) (25,388) Total provision $ 95,374 $ 159,515 $ 107,432 The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows: Years Ended December 26, December 28, 2020 2019 Deferred income tax asset: Investment in partnerships $ (6,294) $ 1,420 Net operating losses and other carryforwards 64,297 43,663 Inventory, premium coupon redemptions and accounts receivable valuation allowances 56,668 23,808 Stock-based compensation 4,858 14,075 Uniform capitalization adjustment to inventories 6,895 7,259 Operating lease right of use asset 74,674 56,780 Other asset 49,260 33,311 Total deferred income tax asset 250,358 180,316 Valuation allowance for deferred tax assets (1) (40,496) (20,699) Net deferred income tax asset 209,862 159,617 Deferred income tax liability Intangibles amortization (118,165) (135,754) Operating lease liability (71,343) (54,672) Property and equipment (7,820) (10,555) Total deferred tax liability (197,328) (200,981) Net deferred income tax asset (liability) $ 12,534 $ (41,364) (1) Primarily relates to operating losses , the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense. The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and the results of recent operations. Since this evaluation requires consideration of events that may occur some years into the future, there is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than not that we will be able to recover all of the value assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly. As of December 26, 2020, we had federal, state, and foreign net operating loss carryforwards of approximately $ 29.8 million, $ 31.6 million and $ 200.5 million, respectively. The federal, state and foreign net operating loss carryforwards will begin to expire in various years from 2024 through 2040 . The amounts of state and foreign net operating losses that can be carried forward indefinitely are $ 10.6 million and $ 199.3 million, respectively. The tax provisions differ from the amount computed using the federal statutory income tax rate as follows: Years ended December 26, December 28, December 29, 2020 2019 2018 Income tax provision at federal statutory rate $ 104,977 $ 142,865 $ 112,735 State income tax provision, net of federal income tax effect 13,015 16,539 15,872 Foreign income tax benefit (428) (4,580) (2,558) Pass-through noncontrolling interest (2,681) (3,931) (2,700) Valuation allowance 659 (79) 2,017 Unrecognized tax benefits and audit settlements (17,722) 3,671 2,126 Interest expense related to loans (11,098) (5,498) (11,700) Excess tax benefits related to stock compensation 778 (86) (1,008) Transition tax on deemed repatriation of foreign earnings - - (10,000) Revaluation of deferred tax assets and liabilities - - (1,676) Tax on global intangible low-taxed income ("GILTI") 2,365 3,917 7,599 Tax benefit related to legal entity reorganization outside the U.S. (5,823) - (13,852) Tax charge related to reorganization of legal entities related to forming Henry Schein One - - 3,914 Tax charge (credit) related to reorganization of legal entities completed in preparation for the Animal Health spin-off - (1,333) 3,135 Other 11,332 8,030 3,528 Total income tax provision $ 95,374 $ 159,515 $ 107,432 For the year ended December 26, 2020, our effective tax rate was 19.1 % compared to 23.4 % for the prior year period. Our effective tax rate in 2020 was primarily impacted by an Advance Pricing Agreement (“APA”) with the U.S Internal Revenue Service (the “IRS”) in the U.S., other audit resolutions, state and foreign income taxes and interest expense. The positive effect of the APA and the other audit resolutions are not expected to be recurring and, as a result, we expect our effective tax rate in future periods to be higher. In 2019, our effective tax rate of 23.4 % was primarily impacted by state and foreign income taxes and interest expense. In 2018, our effective tax rate of 20.0 % was primarily impacted by a reduction in the estimate of our transition tax associated with the Tax Act, tax charges and credits associated with legal entity reorganizations outside the U.S., and state and foreign income taxes and interest expense. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax provisions that modify the Section 163(j) limitation of business interest and Net Operating Loss (“NOL”) carryover and carryback rules. The modifications to Section 163(j) increase the allowable business interest deduction from 30 % of adjusted taxable income to 50 % of adjusted taxable income for years beginning in 2019 and 2020. The CARES Act eliminated the NOL income limitation for years beginning before 2021 and it extended the carryback period to five years for losses incurred in 2018, 2019 and 2020. We have analyzed the income tax provisions of the CARES Act and have accounted for the impact in the year ended December 26, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to us under the CARES Act that require further clarification or interpretation that may affect our consolidated financial statements in the future. On December 27, 2020, the Consolidated Appropriations Act was enacted into law and extended certain non-income tax benefits under the CARES Act. On July 20, 2020, the IRS issued final regulations related to the Tax Act. The final regulations concern the global intangible low-taxed income (“GILTI”) and subpart F income provisions of the Tax Act. To provide flexibility to taxpayers, the IRS is permitting the application of these final regulations to prior tax years, if the taxpayer elects to do so. We have analyzed the final regulations, which do not have a material impact to our consolidated financial statements. On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35 % to 21 %, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. In the fourth quarter of 2017, we recorded provisional amounts for any items that could be reasonably estimated at the time. This included the one-time transition tax that we estimated to be $ 140.0 million and a net deferred tax expense of $ 3.0 million attributable to the revaluation of deferred taxes due to the lower enacted federal income tax rate of 21%. We completed our analysis in the year ended December 29, 2018 and recorded a net $ 10.0 million reduction to the one-time transition tax and an additional $ 1.7 million net deferred tax benefit from the revaluation of deferred taxes to reflect the new tax rate. Within our consolidated balance sheets, transition tax of $ 9.9 million was included in “Accrued taxes” for 2020 and 2019 and $ 74.5 million and $ 94.9 million were included in “Other liabilities” for 2020 and 2019, respectively. The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. We recorded a current tax expense for the GILTI provision of $ 2.4 million $ 3.9 million and $ 7.6 million for 2020, 2019, and 2018, respectively. Due to the one-time transition tax and the imposition of the GILTI provisions, all previously unremitted earnings will no longer be subject to U.S. federal income tax; however, there could be U.S. state and/or foreign withholding taxes upon distribution of such unremitted earnings. Determination of the amount of unrecognized deferred tax liability with respect to such earnings is not practicable. ASC 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect to certain tax matters. The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets as of December 26, 2020 was approximately $ 84.0 million, of which $ 70.1 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits may change in the next 12 months, which may result in a material impact on our consolidated statement of income. The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the IRS, as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2011 and 2014 through 2016. All IRS audit fieldwork has been completed for the years 2012 and 2013. In the quarter ended December 28, 2019, we reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and 2013. For all remaining outstanding issues for 2012 and 2013, we have provided all necessary documentation to the Appellate Division to date and are waiting for responses. We do not believe the final resolution will have a material impact to our consolidated financial statements. During the quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution is to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a favorable resolution with the IRS relating to select audit years. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense (credit) was approximately $( 3.3 ) million, $ 2.2 million, and $ 3.6 million in 2020, 2019 and 2018, respectively. The total amount of accrued interest is included in “Other liabilities”, and was approximately $ 14.0 million as of December 26, 2020 and $ 18.0 million as of December 28, 2019. No penalties were accrued for the periods presented. The following table provides a reconciliation of unrecognized tax benefits: December 26, December 28, December 29, 2020 2019 2018 Balance, beginning of period $ 91,100 $ 77,800 $ 83,200 Additions based on current year tax positions 4,900 4,900 5,000 Additions based on prior year tax positions 7,900 17,300 9,400 Reductions based on prior year tax positions (1,000) (1,000) (1,600) Reductions resulting from settlements with taxing authorities (18,600) (4,200) (1,600) Reductions resulting from lapse in statutes of limitations (14,300) (3,700) (16,600) Balance, end of period $ 70,000 $ 91,100 $ 77,800

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Dec. 26, 2020
Risks and Uncertainties [Abstract]
Concentrations of Risk	Note 15 – Concentrations of Risk Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial instruments. We routinely maintain cash balances at financial institutions in excess of insured amounts. We have not experienced any loss in such accounts and we manage this risk through maintaining cash deposits and other highly liquid investments in high quality financial institutions. We continuously assess the need for reserves for such losses, which have been within our expectations. We do not require collateral or other security to support financial instruments subject to credit risk, except for long-term notes receivable. We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counter-parties. With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base and its dispersion across different types of health care professionals and geographic areas. For the year ended December 26, 2020, two customers accounted for slightly more than 3 % of our net sales from continuing operations. For the year ended December 28, 2019, one customer accounted for slightly less than 2 % of our net sales from continuing operations. With respect to our sources of supply, our top 10 health care distribution suppliers from continuing operations and our single largest supplier from continuing operations accounted for approximately 30 % and 4 %, respectively, of our aggregate purchases in 2020 and approximately 31 % and 6 %, respectively, of our aggregate purchases in 2019. Our long-term notes receivable primarily represent strategic financing arrangements with certain industry affiliates and amounts owed to us from sales of certain businesses. Generally, these notes are secured by certain assets of the counterparty; however, in most cases our security is subordinate to other commercial financial institutions. While we have exposure to credit loss in the event of non-performance by these counter-parties, we conduct ongoing assessments of their financial and operational performance.

Derivatives and Hedging Activities	12 Months Ended
Derivatives and Hedging Activities	Dec. 26, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Note 16 – Derivatives and Hedging Activities We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital. During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in Accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023 , is approximately € 200 million. During the years ended December 26, 2020 and December 28, 2019 we recognized approximately $ 4.7 million and $ 0.6 million, respectively, of interest savings as a result of this net investment hedge. On March 20, 2020 , we entered into a total return swap for the purpose of economically hedging our unfunded non- qualified SERP and DCP. This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $ 43.4 million. At December 26, 2020, the notional value of the investments in these plans was $ 67.6 million. At December 26, 2020, the financing rate for this swap is based on LIBOR of 0.15 % plus 0.38 %, for a combined rate of 0.53 %. From March 20, 2020, the effective date of the swap, to December 26, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $ 21.2 million, net of transaction costs, related to this undesignated swap for the year ended December 26, 2020. This gain was partially offset by the change in fair value adjustment of $ 10.6 million in the SERP and the DCP, which occurred prior to the inception of the swap on March 20, 2020. This swap is expected to be renewed on an annual basis and is expected to result in a neutral impact to our results of operations. Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Revenue from Contracts with Customers	12 Months Ended
Revenue from Contracts with Customers	Dec. 26, 2020
Revenue from Contracts with Customers [Abstract]
Revenue from Contracts with Customer	Revenue (Net sales) is recognized in accordance with the policies discussed in Disaggregation of Net sales The following table disaggregates our Net sales by reportable segment and geographic area: Year Ended December 26, 2020 North America International Global Revenues: Health care distribution Dental $ 3,471,521 2,441,072 5,912,593 Medical 3,514,670 102,347 3,617,017 Total health care distribution 6,986,191 2,543,419 9,529,610 Technology and value-added services 446,830 67,428 514,258 Total excluding Corporate TSA revenues (1) 7,433,021 2,610,847 10,043,868 Corporate TSA revenues (1) - 75,273 75,273 Total revenues $ 7,433,021 $ 2,686,120 $ 10,119,141 Year Ended December 28, 2019 North America International Global Revenues: Health care distribution Dental $ 3,911,746 2,504,119 6,415,865 Medical 2,894,137 79,449 2,973,586 Total health care distribution 6,805,883 2,583,568 9,389,451 Technology and value-added services 445,317 69,768 515,085 Total excluding Corporate TSA revenues (1) 7,251,200 2,653,336 9,904,536 Corporate TSA revenues (1) 4,098 77,169 81,267 Total revenues $ 7,255,298 $ 2,730,505 $ 9,985,803 (1) Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Segment and Geographic Data	12 Months Ended
Segment and Geographic Data	Dec. 26, 2020
Segment Reporting [Abstract]
Segment and Geographic Data	Note 18 – Segment and Geographic Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 31 countries worldwide. Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Years Ended December 26, December 28, December 29, 2020 2019 2018 Net Sales: Health care distribution (1) Dental $ 5,912,593 $ 6,415,865 $ 6,347,998 Medical 3,617,017 2,973,586 2,661,166 Total health care distribution 9,529,610 9,389,451 9,009,164 Technology and value-added services (2) 514,258 515,085 408,439 Total excluding Corporate TSA revenues 10,043,868 9,904,536 9,417,603 Corporate TSA revenues (3) 75,273 81,267 - Total $ 10,119,141 $ 9,985,803 $ 9,417,603 (1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. (3) Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. Years ended December 26, December 28, December 29, 2020 2019 2018 Operating Income: Health care distribution $ 436,173 $ 591,404 $ 490,988 Technology and value-added services 99,130 126,857 109,631 Total $ 535,303 $ 718,261 $ 600,619 Income from continuing operations before taxes and equity in earnings of affiliates: Health care distribution $ 400,343 $ 553,181 $ 429,429 Technology and value-added services 99,552 127,126 107,407 Total $ 499,895 $ 680,307 $ 536,836 Depreciation and Amortization: Health care distribution $ 142,712 $ 146,960 $ 122,767 Technology and value-added services 42,826 37,982 20,863 Total $ 185,538 $ 184,942 $ 143,630 Interest Income: Health care distribution $ 9,736 $ 15,352 $ 15,106 Technology and value-added services 106 405 385 Total $ 9,842 $ 15,757 $ 15,491 Interest Expense: Health care distribution $ 41,307 $ 50,666 $ 76,006 Technology and value-added services 70 126 10 Total $ 41,377 $ 50,792 $ 76,016 Income Tax Expense: Health care distribution $ 71,206 $ 129,381 $ 53,660 Technology and value-added services 24,168 30,134 53,772 Total $ 95,374 $ 159,515 $ 107,432 Purchases of Fixed Assets: Health care distribution $ 43,511 $ 69,095 $ 68,577 Technology and value-added services 5,318 7,124 2,706 Total $ 48,829 $ 76,219 $ 71,283 As of December 26, December 28, December 29, 2020 2019 2018 Total Assets: Health care distribution $ 6,503,089 $ 5,821,468 $ 5,288,662 Technology and value-added services 1,269,443 1,329,633 995,192 Discontinued operations - - 2,216,673 Total $ 7,772,532 $ 7,151,101 $ 8,500,527 The following table presents information about our operations by geographic area as of and for the three years ended December 26, 2020. Net sales by geographic area are based on the respective locations of our subsidiaries. No country, except for the United States, generated net sales greater than 10 % of consolidated net sales. There were no material amounts of sales or transfers among geographic areas and there were no material amounts of export sales. 2020 2019 2018 Net Sales Long-Lived Assets Net Sales Long-Lived Assets Net Sales Long-Lived Assets United States $ 7,090,206 $ 2,362,823 $ 6,876,194 $ 2,400,733 $ 6,411,558 $ 1,753,697 Other 3,028,935 1,251,849 3,109,609 1,195,947 3,006,045 1,017,584 Consolidated total $ 10,119,141 $ 3,614,672 $ 9,985,803 $ 3,596,680 $ 9,417,603 $ 2,771,281

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 26, 2020
Compensation Related Costs [Abstract]
Employee Benefit Plans	Note 19 – Employee Benefit Plans Stock-based Compensation Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $ 8.8 million ($ 7.1 million after-tax) for the year ended December 26, 2020, and pre-tax share-based expense of $ 44.9 million ($ 34.4 million after-tax) and $ 32.6 million ($ 25.3 million after-tax) for the years ended December 28, 2019 and December 29, 2018. Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Stock-based compensation represents the cost related to stock-based awards granted to employees and non- employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income. Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020 Stock Incentive Plan (formerly known as the 2013 Stock Incentive Plan), and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Equity-based awards are granted solely in the form of restricted stock units, with the exception of providing stock options to employees pursuant to certain pre-existing contractual obligations. As of December 26, 2020, there were 65,243 shares authorized and 5,812 shares available to be granted under the 2020 Stock Incentive Plan and 1,893 shares authorized and 265 shares available to be granted under the 2015 Non-Employee Director Stock Incentive Plan. Grants of restricted stock units are stock-based awards granted to recipients with specified vesting provisions. In the case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting conditions. We issue restricted stock units that vest solely based on the recipient’s continued service over time (primarily four year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily 12 month cliff vesting) and restricted stock units that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily three year cliff vesting). With respect to time-based restricted stock units, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock units, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock units based on our closing stock price at time of grant. The Plans provide for adjustments to the performance-based restricted stock units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in tax rates in certain countries, changes in accounting principles or in applicable laws or regulations and foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. As a result of the Separation, the number of our unvested (as of the date of the Separation) equity-based awards from previous grants made under our Long-term Incentive Program under the Plans was increased by a factor of approximately 1.2633 , along with a corresponding decrease in our price per share. We record deferred income tax assets for awards that will result in future deductions on our income tax returns based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Stock-based compensation grants for the three years ended December 26, 2020 consisted of restricted stock/unit grants. Certain stock-based compensation granted may require us to settle in the form of a cash payment. During the year ended December 26, 2020, we recorded a liability of $ 0.8 million relating to the grant date fair value of stock-based compensation to be settled in cash. The weighted-average grant date fair value of stock-based awards granted before forfeitures was $ 60.23 , $ 56.83 and $ 71.38 per share during the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Total unrecognized compensation cost related to non-vested awards as of December 26, 2020 was $ 42.2 million, which is expected to be recognized over a weighted-average period of approximately 2.3 years. A summary of the stock option activity under the Plans is presented below: Years Ended December 26, December 28, December 29, 2020 2019 2018 Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at beginning of year - $ - 3 $ 13.63 155 $ 29.65 Granted - - - - - - Exercised - - (3) 13.63 (152) 29.81 Forfeited - - - - - - Outstanding at end of year - $ - - $ - 3 $ 17.22 Options exercisable at end of year - $ - - $ - 3 $ 17.22 The following table represents the intrinsic values of: As of December 26, December 28, December 29, 2020 2019 2018 Stock options outstanding $ - $ - $ 121 Stock options exercisable - - 121 The total cash received as a result of stock option exercises for the year ended December 29, 2018 was approximately $ 3.1 million. In connection with these exercises, we did no t realize any tax benefits for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. We settle employee stock option exercises with newly issued common shares. The total intrinsic value per share of restricted stock/units that vested was $ 61.49 , $ 64.31 and $ 76.48 during the years ended December 26, 2020, December 28, 2019 and December 29, 2018. The following table summarizes the status of our non-vested restricted stock/units for the year ended December 26, 2020: Time-Based Restricted Stock/Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,417 $ 58.72 Granted 391 60.19 Vested (298) 65.91 Forfeited (51) 59.71 Outstanding at end of period 1,459 $ 57.61 $ 65.83 Performance-Based Restricted Stock/Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,459 $ 61.41 Granted (954) 56.52 Vested (327) 67.48 Forfeited (42) 57.82 Outstanding at end of period 136 $ 53.52 $ 65.83 401(k) Plans We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our Board of Directors, matching contributions to these plans generally do not exceed 100 % of the participants’ contributions up to 7 % of their base compensation, subject to applicable legal limits. Matching contributions consist of cash and were allocated entirely to the participants’ investment elections on file, subject to a 20 % allocation limit to the Henry Schein Stock Fund. Due to the impact of COVID-19, as part of our initiative to generate cash savings, we suspended the matching contribution for the second half of 2020. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are used to reduce our matching contributions and offset administrative expenses of the 401(k) plans. Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to choose from various investment fund options. Matching contributions related to these plans charged to operations during the years ended December 26, 2020, December 28, 2019 and December 29, 2018 amounted to $ 19.9 million, $ 34.9 million and $ 35.0 million, respectively. Supplemental Executive Retirement Plan We offer an unfunded, non-qualified SERP to eligible employees. This plan generally covers officers and certain highly compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to base compensation for the portion of the year in which such employees are not eligible to make pre-tax contributions to the 401(k) plan. Due to the impact of COVID-19, as part of our initiative to generate cash savings, we suspended contributions under the SERP for the second half of 2020. The amounts charged to operations during the years ended December 26, 2020, December 28, 2019 and December 29, 2018 amounted to $ 2.8 million, $ 4.0 million and $ 0.4 million, respectively. Deferred Compensation Plan During 2011, we began to offer DCP to a select group of management or highly compensated employees of the Company and certain subsidiaries. This plan allows for the elective deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged (credited) to operations during the years ended December 26, 2020, December 28, 2019 and December 29, 2018 were approximately $ 7.8 million, $ 8.3 million and $ (2.3) million, respectively.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 26, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 20 – Commitments and Contingencies Purchase Commitments In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the availability of products for distribution. Future minimum annual payments for inventory purchase commitments as of December 26, 2020 were: 2021 $ 208,200 2022 110,800 2023 - 2024 - 2025 - Thereafter - Total minimum inventory purchase commitment payments $ 319,000 Employment, Consulting and Non-Compete Agreements We have definite-lived employment, consulting and non-compete agreements that have varying base aggregate annual payments for the years 2021 through 2025 and thereafter of approximately $ 16.9 million, $ 6.8 million, $ 1.0 million, $ 0.9 million, $ 0.9 million, and $ 0.9 million, respectively. We also have lifetime consulting agreements that provide for current compensation of $ 0.4 million per year, increasing $ 25 every fifth year with the next increase in 2022. In addition, some agreements have provisions for additional incentives and compensation. Litigation On August 31, 2012 , Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights . On August 1, 2017 , Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer seeks damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017 , Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint. On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020. Archer conditionally cross petitioned for certiorari on an arbitration issue on March 2, 2020. On June 15, 2020, the Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional petition for certiorari, and thus the District Court proceedings remained stayed. After briefing from the parties and several amici, the case was argued before the Supreme Court on December 8, 2020. On January 25, 2021, the Supreme Court dismissed the writ of certiorari as improvidently granted. That action dissolved the stay the Supreme Court had previously granted, and thus the trial of the lawsuit may proceed. The U.S. District Court for the Eastern District of Texas has scheduled a Status Conference for February 19, 2021. Patterson and the Danaher Defendants settled with Archer and they have been dismissed from the case with prejudice. Benco is still a defendant. We intend to defend ourselves vigorously against this action. On May 29, 2018 , an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled The County of Summit, Ohio et al . v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants . Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation and paid $250,000 of Summit County’s expenses, as described in our prior filings with the SEC. In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty ( 150 )), which allege claims similar to those alleged in the County of Summit Action. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court gave plaintiffs until November 24, 2020 to replead their claims against Henry Schein. On January 8, 2021, Henry Schein filed a motion to dismiss the Amended Complaint. An action filed by Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated that trial date. At this time, the only case set for trial is the action filed by West Virginia University Hospitals, Inc. et al., which is currently scheduled for a non-jury liability trial on Plaintiffs’ public nuisance claims on November 1, 2021. Of Henry Schein’s 2020 revenue of approximately $ 10.1 billion from continuing operations, sales of opioids represented less than one-tenth of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. On September 30, 2019 , the City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated , filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead counsel on December 23, 2019. Lead plaintiff filed a Consolidated Class Action Complaint on February 21, 2020. Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action. Lead plaintiff filed an Amended Consolidated Class Action Complaint on May 21, 2020, in which it added a claim that Mr. Paladino is a “control person” of Covetrus. We intend to defend ourselves vigorously against this action. On November 15, 2019 , Frank Finazzo filed a putative shareholder derivative action on behalf of Henry Schein, Inc. against various present and former directors and officers of Henry Schein in the U.S. District Court for the Eastern District of New York, Case No. 1:19-cv-6485-LDH-JO. The named defendants in the action were Stanley M. Bergman, Steven Paladino, Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph L. Herring, Donald J. Kabat, Kurt Kuehn, Philip A. Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews, Mark E. Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares, and Louis W. Sullivan, with Henry Schein named as a nominal defendant. The Complaint asserted claims under the federal securities laws and state law relating to the allegations in the antitrust actions, the In re Henry Schein, Inc. Securities Litigation, and the City of Hollywood securities class action described in our prior filings with the SEC and/or above. The complaint sought declaratory, injunctive, and monetary relief on behalf of Henry Schein. On January 6, 2020, one of the two law firms that filed the Finazzo case filed another, virtually identical putative shareholder derivative action on behalf of Henry Schein against the same defendants, asserting the same claims and seeking the same relief. That case, captioned Mark Sloan v. Stanley M. Bergman, et al., was also filed in the U.S. District Court for the Eastern District of New York, Case No. 1:20-cv-0076. On January 24, 2020, the court consolidated the Finazzo and Sloan cases under the new caption In re Henry Schein, Inc. Derivative Litigation, No. 1:19-cv-06485-LDH-JO, and appointed the two law firms that filed the Finazzo case as co-lead counsel for the consolidated action. The parties agreed to a resolution of this matter subject to various conditions, including court approval. The settlement involves the adoption of certain procedures but does not involve the payment of any money except a fee to the plaintiffs’ attorneys that is immaterial. After the court referred the motion to approve the settlement to a Magistrate Judge, the parties consented to having the case assigned to the Magistrate Judge for all purposes. The Magistrate Judge to which the matter was ultimately assigned held a fairness hearing and issued an order and judgment approving the settlement. The order and judgment approving the settlement have become final. On February 5, 2021, Jack Garnsey filed a putative shareholder derivative action on behalf of Covetrus, Inc. in the U.S. District Court for the Eastern District of New York, naming as defendants Benjamin Shaw, Christine T. Komola, Steven Paladino, Betsy Atkins, Deborah G. Ellinger, Sandra L. Helton, Philip A. Laskaway, Mark J. Manoff, Edward M. McNamara, Ravi Sachdev, David E. Shaw, Benjamin Wolin, and Henry Schein, Inc., with Covetrus, Inc. named as a nominal defendant. The complaint alleges that the individual defendants breached their fiduciary duties under state law in connection with the same allegations asserted in the City of Hollywood securities class action described above and further alleges that Henry Schein aided and abetted such breaches. The complaint also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants, also arising out of the allegations in the City of Hollywood lawsuit. The complaint seeks declaratory, injunctive, and monetary relief. We intend to defend ourselves vigorously against this action. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of December 26, 2020, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Quarterly Information (Unaudited)	12 Months Ended
Quarterly Information (Unaudited)	Dec. 26, 2020
Quarterly Financial Data [Abstract]
Quarterly Information (Unaudited)	Note 21 – Quarterly Information (Unaudited) The following tables present certain quarterly financial data: Quarters ended March 28, June 27, September 26, December 26, 2020 2020 2020 2020 Net sales $ 2,428,871 $ 1,684,399 $ 2,840,146 $ 3,165,725 Gross profit 746,039 454,294 754,299 859,711 Restructuring costs (1) 4,787 15,934 6,992 4,380 Operating income (loss) 173,865 (7,433) 187,671 181,200 Net gain on sale of equity investments (2) - - - 1,572 Net income (loss) from continuing operations 133,847 (13,852) 151,813 146,629 Amounts attributable to Henry Schein, Inc. from continuing operations: Net income (loss) 130,543 (11,382) 141,726 141,921 Earnings (loss) per share attributable to Henry Schein, Inc. from continuing operations: Basic $ 0.91 $ (0.08) $ 1.00 $ 1.00 Diluted 0.91 (0.08) 0.99 0.99 Quarters ended March 30, June 29, September 28, December 28, 2019 2019 2019 2019 Net sales $ 2,360,268 $ 2,447,827 $ 2,508,767 $ 2,668,941 Gross profit 751,690 767,431 761,167 810,598 Restructuring costs (credits) (1) 4,641 11,925 (802) (1,059) Operating income 172,441 162,288 187,198 196,334 Net gain on sale of equity investments (2) - - - 186,769 Net income from continuing operations 123,640 121,417 143,212 337,192 Amounts attributable to Henry Schein, Inc. from continuing operations: Net income 118,413 116,753 134,916 330,609 Earnings per share attributable to Henry Schein, Inc. from continuing operations: Basic $ 0.79 $ 0.79 $ 0.92 $ 2.27 Diluted 0.78 0.78 0.91 2.25

Supplemental Cash Flow Information	12 Months Ended
Supplemental Cash Flow Information	Dec. 26, 2020
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Note 22 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Years ended December 26, December 28, December 29, 2020 2019 2018 Interest $ 43,123 $ 54,685 $ 69,371 Income taxes 206,796 177,277 236,479 For the years ended December 26, 2020, December 28, 2019 and December 29, 2018, we had $ (10.2) million, $ (4.9) million and $ 1.0 million of non-cash net unrealized gains (losses) related to foreign currency hedging activities, respectively. During the third quarter of 2018, we formed Henry Schein One, LLC with Internet Brands through a non-cash transaction resulting in approximately $ 390.3 million of noncontrolling interest representing Internet Brands’ current 26 % minority interest and $ 160.6 million of deferred additional ownership interests of Internet Brands in Henry Schein One, representing up to an additional 9.2 % ownership interests at December 26, 2020, a portion of which is contingent upon the achievement of certain operating targets. During the third quarter of 2020, the Internet Brands ownership interest in Henry Schein One, LLC increased to 27 %.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 26, 2020
Related Party Transactions
Related Party Transactions	Note 23 – Related Party Transactions In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services For the years ended December 26, 2020 and December 28, 2019, we recorded approximately $ 13.0 million and $ 17.5 million of fees for these services, respectively. Pursuant to the transition services agreement, Covetrus purchased certain products from us. During the years ended December 26, 2020 and December 28, 2019, net sales to Covetrus under the transition services agreement were approximately $ 75.3 million and $ 81.3 million, respectively. Sales to Covetrus under the transition services agreement ended in December 2020. At December 26, 2020 we had $ 0.3 million payable to Covetrus under this transition services agreement. In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $31.0 million annually for the use of their intellectual property. During 2020, 2019 and 2018, we recorded $ 31.0 , million, $ 31.0 million and $ 15.5 million, respectively in connection with costs related to this royalty agreement. As of December 26, 2020 and December 28, 2019, Henry Schein One, LLC had a net receivable balance due from Internet Brands of $ 4.7 million and $ 9.4 million, respectively, comprised of amounts related to the royalty agreement and other management fees. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During our fiscal years ended 2020, 2019 and 2018, we recorded net sales of $ 59.6 million, $ 93.2 million, and $ 27.0 million, respectively, to such entities. During our fiscal years ended 2020, 2019 and 2018, we purchased $ 12.6 million, $ 11.8 million, and $ 10.8 million, respectively, from such entities. At December 26, 2020 and December 28, 2019, we had in the aggregate $ 36.4 million and $ 31.0 million, due from our equity affiliates, and $ 8.6 million and $ 4.9 million due to our equity affiliates, respectively.

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 26, 2020
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Valuation and Qualifying Accounts (in thousands) Additions (Reductions) Charged Balance at Charged to (credited) to Balance at beginning of statement of other end of Description period income (1) accounts (2) Deductions (3) period Year ended December 26, 2020: Allowance for doubtful accounts and other $ 60,002 $ 35,137 $ 730 $ (7,839) $ 88,030 Yea r ended December 28, 2019: Allowance for doubtful accounts and other $ 53,121 $ 12,612 $ 134 $ (5,865) $ 60,002 Yea r ended December 29, 2018: Allowance for doubtful accounts and other $ 46,261 $ 14,384 $ (1,158) $ (6,366) $ 53,121 (1) Represents amounts charged to bad debt expense. (2) Amounts charged (credited) to other accounts primarily relate to provision for late fees and the impact of foreign currency exchange rates and the adoption of ASU No. 2016-13 effective December 29, 2019. (3) Deductions primarily consist of fully reserved accounts receivable that have been written off.

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 26, 2020
Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements. For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At December 26, 2020 and December 28, 2019, trade accounts receivable that can only be used to settle obligations of this VIE were $ 0.0 million and $ 127 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were $ 0.0 million and $ 100 million, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand increased in the second half of the year resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products. Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the latter half of the year, dental and medical practices began to re-open worldwide, and continued to do so during the remainder of the year. However, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.
Fiscal Year	Fiscal Year We report our results of operations and cash flows on a 52 - 53 week basis ending on the last Saturday of December. The years ended December 26, 2020, December 28, 2019 and December 29, 2018 consisted of 52 weeks.
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following: • identify the contract(s) with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when, or as, the entity satisfies a performance obligation. We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment. Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with Accounting Standards Codification (“ASC”) 460 “Guarantees”. Revenue derived from the sale of software products is recognized when products are shipped to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract. Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations, which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. There are no cases where revenue is deferred due to a lack of a standalone selling price. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Contract Balances Contract balances represent amounts presented in our consolidated balance sheet when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Accounts Receivable Accounts receivable are generally recognized when health care distribution and technology and value-added services revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. Contract Assets Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in Investments and other within our consolidated balance sheets. Current and non-current contract asset balances as of December 26, 2020 and December 28, 2019 were not material. Contract Liabilities Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in Accrued expenses: Other and the non-current contract liabilities are included in Other liabilities within our consolidated balance sheets. At December 28, 2019, the current portion of contract liabilities of $ 70.8 million was reported in Accrued expenses: Other, and $ 6.2 million related to non-current contract liabilities were reported in Other liabilities. During the year ended December 26, 2020, we recognized substantially all of the current contract liability amounts that were previously deferred at December 28, 2019. At December 26, 2020, the current and non-current portion of contract liabilities were $ 71.5 million and $ 8.2 million, respectively. Deferred Commissions Sales commissions earned by our sales force that relate to long term arrangements are capitalized as costs to obtain a contract when the costs incurred are incremental and are expected to be recovered. Deferred sales commissions are amortized over the estimated customer relationship period. We apply the practical expedient related to the capitalization of incremental costs of obtaining a contract, and recognize such costs as an expense when incurred if the amortization period of the assets that we would have recognized is one year or less. Our deferred commission balances as of December 26, 2020 and December 28, 2019 were not material. Sales Returns Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any products that we expect to be returned. Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $ 79.2 million, $ 73.8 million and $ 70.6 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018. Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $ 1.3 million and $ 29.5 million, primarily related to payments for inventory, were classified as accounts payable as of December 26, 2020 and December 28, 2019.
Inventories and Reserves	Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.
Advertising and Promotional Costs	Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $ 30.8 million, $ 25.2 million and $ 12.9 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized.
Income Taxes	Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80 % or greater owned U.S. subsidiaries. On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35 % to 21 %, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. In the fourth quarter of 2017, we recorded provisional amounts for any items that could be reasonably estimated at the time. This included the one-time transition tax that we estimated to be $ 140.0 million and a net deferred tax expense of $ 3.0 million attributable to the revaluation of deferred taxes due to the lower enacted federal income tax rate of 21%. We completed our analysis in the year ended December 29, 2018 and recorded a net $ 10.0 million reduction to the one-time transition tax and an additional $ 1.7 million net deferred tax benefit from the revaluation of deferred taxes to reflect the new tax rate. Within our consolidated balance sheets, transition tax of $ 9.9 million was included in “Accrued taxes” for 2020 and 2019 and $ 74.5 million and $ 94.9 million were included in “Other liabilities” for 2020 and 2019, respectively. The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. We recorded a current tax expense for the GILTI provision of $ 2.4 million $ 3.9 million and $ 7.6 million for 2020, 2019, and 2018, respectively.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings.
Risk Management and Derivative Financial Instruments	Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item. Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings. Total return swaps are entered into for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. This swap is expected to be renewed on an annual basis.
Acquisitions	Acquisitions We account for business acquisitions and combinations under the acquisition method of accounting, where the net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rates; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations. For the years ended December 26, 2020, December 28, 2019 and December 29, 2018, there were no material adjustments recorded in our consolidated statement of income relating to changes in subsequent adjustments or estimated contingent purchase price liabilities.
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. Noncontrolling Interests Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.
Goodwill and Other Indefinite-Lived Intangibles Assets	Goodwill Goodwill is not amortized, but is subject to impairment analysis annually or more frequently if there is a triggering event or if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Such impairment analyses for goodwill requires a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: global dental; global medical; and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. On December 29, 2019 we adopted Account Standards Update (“ASU”) 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminated step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. We perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. Goodwill as of December 26, 2019 and December 29, 2018 were tested under the prior standard. For the year ended December 26, 2020 we tested goodwill for impairment, on the first day of the fourth quarter, using a quantitative analysis comparing the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Conversely, impairment loss would be equivalent to the excess of a reporting unit’s carrying value over its fair value limited to the total amount of goodwill allocated to that reporting unit. For the years ended December 26, 2019 and December 29, 2018 we tested goodwill for impairment on the first day of the fourth quarter, using a quantitative analysis which consisted of a two-step approach. The first step of our quantitative analysis consisted of a comparison of the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If step one resulted in the carrying value of the reporting unit exceeding the fair value of such reporting unit, we would have then proceeded to step two which would have required us to calculate the amount of impairment loss, if any, that we would have recorded for such reporting unit. The calculation of the impairment loss in step two would have been equivalent to the reporting unit’s carrying value of goodwill less the implied fair value of such goodwill. Our use of a discounted cash flow methodology includes estimates of future revenue based upon budget projections and growth rates which take into account estimated inflation rates. We also develop estimates for future levels of gross and operating profits and projected capital expenditures. Our methodology also includes the use of estimated discount rates based upon industry and competitor analysis as well as other factors. The estimates that we use in our discounted cash flow methodology involve many assumptions by management that are based upon future growth projections. Some factors we consider important that could trigger an interim impairment review include: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or significant negative industry or economic trends. If we determine through the impairment review process that goodwill is impaired, we record an impairment charge in our consolidated statements of income. For the years ended December 28, 2019 and December 29, 2018, the results of our goodwill impairment analysis did no t result in any impairments.
Long-Lived Assets	Long-Lived Assets Long-lived assets, other than goodwill and other definite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. During the year ended December 26, 2020, we recorded total impairment charges on intangible assets of approximately $ 20.3 million, nearly all of which was recorded in our technology and value-added services segment.
Cost of Sales	Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $ 71.7 million, $ 72.3 million and $ 69.6 million for the years ended December 26, 2020, December 28, 2019 and December 29, 2018.
Comprehensive Income	Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).
Leases	Leases On December 30, 2018, we adopted ASC Topic 842, Leases, using a modified retrospective approach, whereby we continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption. We elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Information related to leases as of December 28, 2019 is presented under Topic 842, while prior period amounts are not adjusted and continue to be reported under legacy guidance in ASC Topic 840, Leases. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. Adoption of the new standard resulted in the recording of additional net operating lease assets of $ 259.9 million and operating lease liabilities of $ 267.3 million, and a decrease of $ 1.1 million and $ 8.5 million in prepaid rent and deferred rent liabilities, respectively. The standard did not materially impact our consolidated net income and had no impact on cash flows. We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases and finance leases are included in “Selling, general and administrative” and “Interest expense”, respectively within our Consolidated Statement of Income. Leases with a lease term of 12 months or less are not capitalized. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Short-term Leases	Leases with a lease term of 12 months or less are not capitalized.
Separation of Lease and Nonlease Components	We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Accounting Pronouncements Adopted	Accounting Pronouncements Adopted On December 29, 2019, we adopted ASU No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 requires us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. Our adoption of ASU 2017-04 did not have a material impact on our consolidated financial statements. On December 29, 2019, we adopted ASU No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. We adopted Topic 326 using the modified- retrospective method and recorded an immaterial cumulative-effect adjustment to the opening balance of retained earnings. Based upon the level and makeup of our financial asset portfolio, including accounts receivable, past loan loss activity and current known activity regarding our outstanding loans, the adoption of this ASU resulted in a decrease of $ 0.4 million to retained earnings. Recently Issued Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020- 06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings- per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

Discontinued Operations (Tables)	12 Months Ended
Discontinued Operations (Tables)	Dec. 26, 2020
Discontinued Operations [Abstract]
Summarized financial information for discontinued operations	Summarized financial information for our discontinued operations is as follows: Years Ended December 26, December 28, December 29, 2020 2019 2018 Net sales $ - $ 319,522 $ 3,784,392 Cost of goods sold - 260,097 3,100,055 Gross profit - 59,425 684,337 Selling, general and administrative 2,347 68,919 531,905 Operating income (loss) (2,347) (9,494) 152,432 Income tax expense (benefit) (3,333) (2,181) 48,060 Income (loss) from discontinued operations 986 (6,323) 111,685 Net (income) loss attributable to noncontrolling interests - 366 (6,521) Net income (loss) from discontinued operations attributable to Henry Schein, Inc. 986 (5,957) 105,164 The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019. February 7, 2019 Cash and cash equivalents $ 6,815 Accounts receivable, net 432,812 Inventories, net 536,637 Prepaid expenses and other 120,546 Total current assets of discontinued operations 1,096,810 Property and equipment, net 69,790 Operating lease right-of-use asset, net 57,012 Goodwill 742,931 Other intangibles, net 205,793 Investments and other 120,518 Total long-term assets of discontinued operations 1,196,044 Total assets of discontinued operations $ 2,292,854 Accounts payable $ 316,162 Current maturities of long-term debt 657 Operating lease liabilities 18,951 Accrued expenses: Payroll and related 36,847 Taxes 24,060 Other 80,400 Total current liabilities of discontinued operations 477,077 Long-term debt 1,176,105 Deferred income taxes 17,019 Operating lease liabilities 38,668 Other liabilities 29,209 Total long-term liabilities of discontinued operations 1,261,001 Total liabilities of discontinued operations $ 1,738,078 Redeemable noncontrolling interests $ 28,270

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 26, 2020
Property, Plant and Equipment [Abstract]
Property and equipment, including related estimated useful lives	December 26, December 28, 2020 2019 Land $ 20,297 $ 18,030 Buildings and permanent improvements 145,160 121,823 Leasehold improvements 107,753 104,089 Machinery and warehouse equipment 142,437 124,640 Furniture, fixtures and other 108,041 99,083 Computer equipment and software 344,494 330,926 868,182 798,591 Less accumulated depreciation (526,178) (468,946) Property and equipment, net $ 342,004 $ 329,645 Estimated Useful Lives (in years) Buildings and permanent improvements 40 Machinery and warehouse equipment 5 - 10 Furniture, fixtures and other 3 - 10 Computer equipment and software 3 - 10

Goodwill and Other Intangibles, Net (Tables)	12 Months Ended
Goodwill and Other Intangibles, Net (Tables)	Dec. 26, 2020
Goodwill and other Intangibles, Net Disclosure [Abstract]
Changes in the carrying amount of goodwill	Health Care Distribution Technology and Value-Added Services Total Balance as of December 29, 2018 $ 1,433,412 $ 647,617 $ 2,081,029 Adjustments to goodwill: Acquisitions 50,276 338,352 388,628 Foreign currency translation (6,969) (193) (7,162) Balance as of December 28, 2019 1,476,719 985,776 2,462,495 Adjustments to goodwill: Acquisitions 14,230 12,101 26,331 Foreign currency translation 9,888 5,678 15,566 Balance as of December 26, 2020 $ 1,500,837 $ 1,003,555 $ 2,504,392
Other intangible assets - finite-lived	December 26, 2020 December 28, 2019 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Non-compete agreements $ 30,993 $ (11,480) $ 19,513 $ 34,553 $ (9,327) $ 25,226 Trademarks / trade names - definite lived 95,382 (50,893) 44,489 99,314 (44,134) 55,180 Customer relationships and lists 652,605 (283,469) 369,136 715,630 (274,330) 441,300 Product Development 94,216 (54,451) 39,765 85,211 (42,326) 42,885 Other 14,188 (7,662) 6,526 26,237 (17,950) 8,287 Total $ 887,384 $ (407,955) $ 479,429 $ 960,945 $ (388,067) $ 572,878

Investments and Other (Tables)	12 Months Ended
Investments and Other (Tables)	Dec. 26, 2020
Investments And Other [Abstract]
Investments and other	December 26, December 28, 2020 2019 Investment in unconsolidated affiliates $ 169,382 $ 164,659 Non-current deferred foreign, state and local income taxes 42,594 23,625 Notes receivable (1) 34,760 43,544 Capitalized costs for internally generated software for resale 47,650 42,445 Security deposits 1,752 534 Acquisition-related indemnification 49,401 38,464 Other long-term assets 20,906 14,648 Total $ 366,445 $ 327,919 (1) Long-term notes receivable carry interest rates ranging from 1 .0% to 14 .0% and are due in varying installments through September 30, 2027 .

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 26, 2020
Debt [Abstract]
Bank credit lines	December 26, December 28, 2020 2019 Revolving credit agreement $ - $ - Other short-term bank credit lines 73,366 23,975 Total $ 73,366 $ 23,975
Schedule of long-term debt	December 26, December 28, 2020 2019 Private placement facilities $ 613,498 $ 621,274 U.S. trade accounts receivable securitization - 100,000 Note payable due in 2025 with an interest rate of 3.1% at December 26, 2020 1,554 - Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 2.62% to 4.27% at December 26, 2020 and ranging from 2.56% to 10.5% at December 28, 2019 4,596 6,089 Finance lease obligations (see Note 7) 5,961 5,394 Total 625,609 732,757 Less current maturities (109,836) (109,849) Total long-term debt $ 515,773 $ 622,908
Private placement facilities	Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date January 20, 2012 (1) $ 14,286 3.09 % January 20, 2022 January 20, 2012 50,000 3.45 January 20, 2024 December 24, 2012 50,000 3.00 December 24, 2024 June 2, 2014 100,000 3.19 June 2, 2021 June 16, 2017 100,000 3.42 June 16, 2027 September 15, 2017 100,000 3.52 September 15, 2029 January 2, 2018 100,000 3.32 January 2, 2028 September 2, 2020 (2) 100,000 2.35 September 2, 2030 Less: Deferred debt issuance costs (788) $ 613,498 (1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016. (2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.
Schedule of long-term debt maturities	2021 $ 109,836 2022 11,607 2023 1,916 2024 100,303 2025 1,839 Thereafter 400,108 Total $ 625,609

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 26, 2020
Leases [Abstract]
Components of lease expense, supplemental cash flow, and supplemental balance sheet information	Years Ended December 26, December 28, 2020 2019 Operating lease cost: (1) (2) $ 86,800 $ 88,246 Finance lease cost: Amortization of right-of-use assets 2,209 1,154 Interest on lease liabilities 115 131 Total finance lease cost $ 2,324 $ 1,285 (1) Includes variable lease expenses. (2) Operating lease cost for each of the years ended December 26, 2020, and December 28, 2019, includes amortization of right-of-use assets of $ 0.6 million, related to facility leases recorded in “Restructuring costs” within our consolidated statements of income. Years Ended December 26, December 28, 2020 2019 Operating Leases: Operating lease right-of-use assets $ 288,847 $ 231,662 Current operating lease liabilities 64,716 65,349 Non-current operating lease liabilities 238,727 176,267 Total operating lease liabilities $ 303,443 $ 241,616 Finance Leases: Property and equipment, at cost $ 10,683 $ 10,268 Accumulated depreciation (4,277) (4,581) Property and equipment, net of accumulated depreciation $ 6,406 $ 5,687 Current maturities of long-term debt $ 2,420 $ 1,736 Long-term debt 3,541 3,658 Total finance lease liabilities $ 5,961 $ 5,394 Weighted Average Remaining Lease Term in Years: Operating leases 7.5 5.5 Finance leases 4.3 5.0 Weighted Average Discount Rate: Operating leases 2.8 % 3.4 % Finance leases 1.9 % 2.2 % Years Ended December 26, December 28, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 76,985 79,699 Operating cash flows for finance leases 101 99 Financing cash flows for finance leases 2,148 1,413 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 120,148 297,800 Finance leases 2,947 2,940
Maturities of operating lease liabilities	December 26, 2020 Operating Finance Leases Leases 2021 $ 71,801 $ 2,503 2022 58,049 1,542 2023 40,670 596 2024 28,899 327 2025 26,147 305 Thereafter 110,228 920 Total future lease payments 335,794 6,193 Less imputed interest (32,351) (232) Total $ 303,443 $ 5,961
Maturities of finance lease liabilities	December 26, 2020 Operating Finance Leases Leases 2021 $ 71,801 $ 2,503 2022 58,049 1,542 2023 40,670 596 2024 28,899 327 2025 26,147 305 Thereafter 110,228 920 Total future lease payments 335,794 6,193 Less imputed interest (32,351) (232) Total $ 303,443 $ 5,961

Redeemable Noncontrolling Interests (Tables)	12 Months Ended
Redeemable Noncontrolling Interests (Tables)	Dec. 26, 2020
Redeemable Noncontrolling Interests [Abstract]
Change in fair value of redeemable noncontrolling interests	December 26, December 28, December 29, 2020 2019 2018 Balance, beginning of period $ 287,258 $ 219,724 $ 465,585 Decrease in redeemable noncontrolling interests due to redemptions (17,241) (2,270) (287,767) Increase in redeemable noncontrolling interests due to business acquisitions 28,387 74,865 4,655 Net income attributable to redeemable noncontrolling interests 13,363 14,838 15,327 Dividends declared (12,631) (10,264) (8,206) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (4,279) (2,335) (11,330) Change in fair value of redeemable securities 32,842 (7,300) 41,460 Balance, end of period $ 327,699 $ 287,258 $ 219,724

Comprehensive Income (Tables)	12 Months Ended
Comprehensive Income (Tables)	Dec. 26, 2020
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Accumulated other comprehensive income, net of applicable taxes	December 26, December 28, December 29, 2020 2019 2018 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (24,617) $ (20,338) $ (18,595) Attributable to noncontrolling interests: Foreign currency translation adjustment $ 235 $ (531) $ (426) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (76,565) $ (143,172) $ (234,799) Unrealized loss from foreign currency hedging activities (11,488) (4,032) (156) Unrealized investment gain (loss) 1 6 (6) Pension adjustment loss (20,032) (20,175) (13,810) Accumulated other comprehensive loss $ (108,084) $ (167,373) $ (248,771) Total Accumulated other comprehensive loss $ (132,466) $ (188,242) $ (267,792)
Components of comprehensive income, net of applicable taxes	December 26, December 28, December 29, 2020 2019 2018 Net income $ 419,423 $ 719,138 $ 562,126 Foreign currency translation gain (loss) 63,094 (4,070) (136,356) Tax effect - - - Foreign currency translation gain (loss) 63,094 (4,070) (136,356) Unrealized gain (loss) from foreign currency hedging activities (10,224) (4,911) 1,022 Tax effect 2,768 1,035 (396) Unrealized gain (loss) from foreign currency hedging activities (7,456) (3,876) 626 Unrealized investment gain (loss) (6) 14 (3) Tax effect 1 (2) - Unrealized investment gain (loss) (5) 12 (3) Pension adjustment gain (loss) (533) (7,730) 4,212 Tax effect 676 1,806 (1,179) Pension adjustment gain (loss) 143 (5,924) 3,033 Comprehensive income $ 475,199 $ 705,280 $ 429,426
Total comprehensive income, net of applicable taxes	December 26, December 28, December 29, 2020 2019 2018 Comprehensive income attributable to Henry Schein, Inc. $ 463,083 $ 682,724 $ 417,177 Comprehensive income attributable to noncontrolling interests 3,032 9,827 3,432 Comprehensive income attributable to Redeemable noncontrolling interests 9,084 12,729 8,817 Comprehensive income $ 475,199 $ 705,280 $ 429,426

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 26, 2020
Fair Value Measurements [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	December 26, 2020 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 1,868 $ - $ 1,868 Total return swaps - 1,565 - 1,565 Total assets $ - $ 3,433 $ - $ 3,433 Liabilities: Derivative contracts $ - $ 11,765 $ - $ 11,765 Total liabilities $ - $ 11,765 $ - $ 11,765 Redeemable noncontrolling interests $ - $ - $ 327,699 $ 327,699 December 28, 2019 Level 1 Level 2 Level 3 Total Assets: Derivative contracts $ - $ 567 $ - $ 567 Total assets $ - $ 567 $ - $ 567 Liabilities: Derivative contracts $ - $ 5,795 $ - $ 5,795 Total liabilities $ - $ 5,795 $ - $ 5,795 Redeemable noncontrolling interests $ - $ - $ 287,258 $ 287,258

Plans of Restructuring (Tables)	12 Months Ended
Plans of Restructuring (Tables)	Dec. 26, 2020
Restructuring and Related Activities [Abstract]
Schedule of restructuring reserve by type of cost	Facility Severance Closing Costs Costs Other Total Balance, December 30, 2017 $ 3,087 $ 1,315 $ 24 $ 4,426 Provision 50,197 3,153 1,017 54,367 Payments and other adjustments (23,320) (2,865) (883) (27,068) Balance, December 29, 2018 $ 29,964 $ 1,603 $ 158 $ 31,725 Provision 13,741 937 27 14,705 Payments and other adjustments (30,794) (1,714) (112) (32,620) Balance, December 28, 2019 $ 12,911 $ 826 $ 73 $ 13,810 Provision 25,855 5,878 360 32,093 Payments and other adjustments (26,152) (6,309) (329) (32,790) Balance, December 26, 2020 $ 12,614 $ 395 $ 104 $ 13,113
Schedule of restructuring reserve by segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2017 $ 4,426 $ - $ 4,426 Provision 50,824 3,543 54,367 Payments and other adjustments (24,959) (2,109) (27,068) Balance, December 29, 2018 $ 30,291 $ 1,434 $ 31,725 Provision 13,935 770 14,705 Payments and other adjustments (30,853) (1,767) (32,620) Balance, December 28, 2019 $ 13,373 $ 437 $ 13,810 Provision 30,935 1,158 32,093 Payments and other adjustments (31,484) (1,306) (32,790) Balance, December 26, 2020 $ 12,824 $ 289 $ 13,113

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Dec. 26, 2020
Earnings Per Share [Abstract]
Reconciliation of basic and diluted shares used to calculate earnings per share	Years Ended December 26, December 28, December 29, 2020 2019 2018 Basic 142,504 147,817 152,656 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 900 1,440 1,051 Diluted 143,404 149,257 153,707

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 26, 2020
Income Taxes [Abstract]
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment	Years ended December 26, December 28, December 29, 2020 2019 2018 Domestic $ 430,838 $ 507,003 $ 405,289 Foreign 69,057 173,304 131,547 Total $ 499,895 $ 680,307 $ 536,836
Provision for income taxes attributable to continuing operations	The provisions for income taxes were as follows: Years ended December 26, December 28, December 29, 2020 2019 2018 Current income tax expense: U.S. Federal $ 82,912 $ 93,418 $ 71,854 State and local 24,640 28,150 22,533 Foreign 40,799 42,004 38,433 Total current 148,351 163,572 132,820 Deferred income tax expense (benefit): U.S. Federal (18,032) 5,633 206 State and local (4,889) 1,597 (1,622) Foreign (30,056) (11,287) (23,972) Total deferred (52,977) (4,057) (25,388) Total provision $ 95,374 $ 159,515 $ 107,432
Tax effects of temporary differences to deferred income tax asset (liability)	The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows: Years Ended December 26, December 28, 2020 2019 Deferred income tax asset: Investment in partnerships $ (6,294) $ 1,420 Net operating losses and other carryforwards 64,297 43,663 Inventory, premium coupon redemptions and accounts receivable valuation allowances 56,668 23,808 Stock-based compensation 4,858 14,075 Uniform capitalization adjustment to inventories 6,895 7,259 Operating lease right of use asset 74,674 56,780 Other asset 49,260 33,311 Total deferred income tax asset 250,358 180,316 Valuation allowance for deferred tax assets (1) (40,496) (20,699) Net deferred income tax asset 209,862 159,617 Deferred income tax liability Intangibles amortization (118,165) (135,754) Operating lease liability (71,343) (54,672) Property and equipment (7,820) (10,555) Total deferred tax liability (197,328) (200,981) Net deferred income tax asset (liability) $ 12,534 $ (41,364) (1) Primarily relates to operating losses , the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense.
Reconciliation of income tax provision at federal statutory rate to total income tax provision	Years ended December 26, December 28, December 29, 2020 2019 2018 Income tax provision at federal statutory rate $ 104,977 $ 142,865 $ 112,735 State income tax provision, net of federal income tax effect 13,015 16,539 15,872 Foreign income tax benefit (428) (4,580) (2,558) Pass-through noncontrolling interest (2,681) (3,931) (2,700) Valuation allowance 659 (79) 2,017 Unrecognized tax benefits and audit settlements (17,722) 3,671 2,126 Interest expense related to loans (11,098) (5,498) (11,700) Excess tax benefits related to stock compensation 778 (86) (1,008) Transition tax on deemed repatriation of foreign earnings - - (10,000) Revaluation of deferred tax assets and liabilities - - (1,676) Tax on global intangible low-taxed income ("GILTI") 2,365 3,917 7,599 Tax benefit related to legal entity reorganization outside the U.S. (5,823) - (13,852) Tax charge related to reorganization of legal entities related to forming Henry Schein One - - 3,914 Tax charge (credit) related to reorganization of legal entities completed in preparation for the Animal Health spin-off - (1,333) 3,135 Other 11,332 8,030 3,528 Total income tax provision $ 95,374 $ 159,515 $ 107,432
Reconciliation of unrecognized tax benefits excluding the effect of deferred taxes	December 26, December 28, December 29, 2020 2019 2018 Balance, beginning of period $ 91,100 $ 77,800 $ 83,200 Additions based on current year tax positions 4,900 4,900 5,000 Additions based on prior year tax positions 7,900 17,300 9,400 Reductions based on prior year tax positions (1,000) (1,000) (1,600) Reductions resulting from settlements with taxing authorities (18,600) (4,200) (1,600) Reductions resulting from lapse in statutes of limitations (14,300) (3,700) (16,600) Balance, end of period $ 70,000 $ 91,100 $ 77,800

Revenue from Contracts with Customers (Tables)	12 Months Ended
Revenue from Contracts with Customers (Tables)	Dec. 26, 2020
Revenue from Contracts with Customers [Abstract]
Disaggregation of Revenue	Year Ended December 26, 2020 North America International Global Revenues: Health care distribution Dental $ 3,471,521 2,441,072 5,912,593 Medical 3,514,670 102,347 3,617,017 Total health care distribution 6,986,191 2,543,419 9,529,610 Technology and value-added services 446,830 67,428 514,258 Total excluding Corporate TSA revenues (1) 7,433,021 2,610,847 10,043,868 Corporate TSA revenues (1) - 75,273 75,273 Total revenues $ 7,433,021 $ 2,686,120 $ 10,119,141 Year Ended December 28, 2019 North America International Global Revenues: Health care distribution Dental $ 3,911,746 2,504,119 6,415,865 Medical 2,894,137 79,449 2,973,586 Total health care distribution 6,805,883 2,583,568 9,389,451 Technology and value-added services 445,317 69,768 515,085 Total excluding Corporate TSA revenues (1) 7,251,200 2,653,336 9,904,536 Corporate TSA revenues (1) 4,098 77,169 81,267 Total revenues $ 7,255,298 $ 2,730,505 $ 9,985,803 (1) Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.

Segment and Geographic Data (Tables)	12 Months Ended
Segment and Geographic Data (Tables)	Dec. 26, 2020
Segment Reporting [Abstract]
Business segment information	Years Ended December 26, December 28, December 29, 2020 2019 2018 Net Sales: Health care distribution (1) Dental $ 5,912,593 $ 6,415,865 $ 6,347,998 Medical 3,617,017 2,973,586 2,661,166 Total health care distribution 9,529,610 9,389,451 9,009,164 Technology and value-added services (2) 514,258 515,085 408,439 Total excluding Corporate TSA revenues 10,043,868 9,904,536 9,417,603 Corporate TSA revenues (3) 75,273 81,267 - Total $ 10,119,141 $ 9,985,803 $ 9,417,603 (1) Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. (3) Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. Years ended December 26, December 28, December 29, 2020 2019 2018 Operating Income: Health care distribution $ 436,173 $ 591,404 $ 490,988 Technology and value-added services 99,130 126,857 109,631 Total $ 535,303 $ 718,261 $ 600,619 Income from continuing operations before taxes and equity in earnings of affiliates: Health care distribution $ 400,343 $ 553,181 $ 429,429 Technology and value-added services 99,552 127,126 107,407 Total $ 499,895 $ 680,307 $ 536,836 Depreciation and Amortization: Health care distribution $ 142,712 $ 146,960 $ 122,767 Technology and value-added services 42,826 37,982 20,863 Total $ 185,538 $ 184,942 $ 143,630 Interest Income: Health care distribution $ 9,736 $ 15,352 $ 15,106 Technology and value-added services 106 405 385 Total $ 9,842 $ 15,757 $ 15,491 Interest Expense: Health care distribution $ 41,307 $ 50,666 $ 76,006 Technology and value-added services 70 126 10 Total $ 41,377 $ 50,792 $ 76,016 Income Tax Expense: Health care distribution $ 71,206 $ 129,381 $ 53,660 Technology and value-added services 24,168 30,134 53,772 Total $ 95,374 $ 159,515 $ 107,432 Purchases of Fixed Assets: Health care distribution $ 43,511 $ 69,095 $ 68,577 Technology and value-added services 5,318 7,124 2,706 Total $ 48,829 $ 76,219 $ 71,283 As of December 26, December 28, December 29, 2020 2019 2018 Total Assets: Health care distribution $ 6,503,089 $ 5,821,468 $ 5,288,662 Technology and value-added services 1,269,443 1,329,633 995,192 Discontinued operations - - 2,216,673 Total $ 7,772,532 $ 7,151,101 $ 8,500,527
Operations by geographic area	2020 2019 2018 Net Sales Long-Lived Assets Net Sales Long-Lived Assets Net Sales Long-Lived Assets United States $ 7,090,206 $ 2,362,823 $ 6,876,194 $ 2,400,733 $ 6,411,558 $ 1,753,697 Other 3,028,935 1,251,849 3,109,609 1,195,947 3,006,045 1,017,584 Consolidated total $ 10,119,141 $ 3,614,672 $ 9,985,803 $ 3,596,680 $ 9,417,603 $ 2,771,281

Employee Benefit Plans (Tables)	12 Months Ended
Employee Benefit Plans (Tables)	Dec. 26, 2020
Compensation Related Costs [Abstract]
Summary of the stock option activity under the plans	Years Ended December 26, December 28, December 29, 2020 2019 2018 Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at beginning of year - $ - 3 $ 13.63 155 $ 29.65 Granted - - - - - - Exercised - - (3) 13.63 (152) 29.81 Forfeited - - - - - - Outstanding at end of year - $ - - $ - 3 $ 17.22 Options exercisable at end of year - $ - - $ - 3 $ 17.22
Intrinsic values	As of December 26, December 28, December 29, 2020 2019 2018 Stock options outstanding $ - $ - $ 121 Stock options exercisable - - 121
Status of non-vested restricted shares/units	Time-Based Restricted Stock/Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,417 $ 58.72 Granted 391 60.19 Vested (298) 65.91 Forfeited (51) 59.71 Outstanding at end of period 1,459 $ 57.61 $ 65.83 Performance-Based Restricted Stock/Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,459 $ 61.41 Granted (954) 56.52 Vested (327) 67.48 Forfeited (42) 57.82 Outstanding at end of period 136 $ 53.52 $ 65.83

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 26, 2020
Commitments and Contingencies Disclosure [Abstract]
Purchase commitments	2021 $ 208,200 2022 110,800 2023 - 2024 - 2025 - Thereafter - Total minimum inventory purchase commitment payments $ 319,000

Quarterly Information (Unaudited) (Tables)	12 Months Ended
Quarterly Information (Unaudited) (Tables)	Dec. 26, 2020
Quarterly Financial Data [Abstract]
Quarterly financial information (unaudited)	Quarters ended March 28, June 27, September 26, December 26, 2020 2020 2020 2020 Net sales $ 2,428,871 $ 1,684,399 $ 2,840,146 $ 3,165,725 Gross profit 746,039 454,294 754,299 859,711 Restructuring costs (1) 4,787 15,934 6,992 4,380 Operating income (loss) 173,865 (7,433) 187,671 181,200 Net gain on sale of equity investments (2) - - - 1,572 Net income (loss) from continuing operations 133,847 (13,852) 151,813 146,629 Amounts attributable to Henry Schein, Inc. from continuing operations: Net income (loss) 130,543 (11,382) 141,726 141,921 Earnings (loss) per share attributable to Henry Schein, Inc. from continuing operations: Basic $ 0.91 $ (0.08) $ 1.00 $ 1.00 Diluted 0.91 (0.08) 0.99 0.99 Quarters ended March 30, June 29, September 28, December 28, 2019 2019 2019 2019 Net sales $ 2,360,268 $ 2,447,827 $ 2,508,767 $ 2,668,941 Gross profit 751,690 767,431 761,167 810,598 Restructuring costs (credits) (1) 4,641 11,925 (802) (1,059) Operating income 172,441 162,288 187,198 196,334 Net gain on sale of equity investments (2) - - - 186,769 Net income from continuing operations 123,640 121,417 143,212 337,192 Amounts attributable to Henry Schein, Inc. from continuing operations: Net income 118,413 116,753 134,916 330,609 Earnings per share attributable to Henry Schein, Inc. from continuing operations: Basic $ 0.79 $ 0.79 $ 0.92 $ 2.27 Diluted 0.78 0.78 0.91 2.25

Supplemental Cash Flow Information (Tables)	12 Months Ended
Supplemental Cash Flow Information (Tables)	Dec. 26, 2020
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest and income taxes	Years ended December 26, December 28, December 29, 2020 2019 2018 Interest $ 43,123 $ 54,685 $ 69,371 Income taxes 206,796 177,277 236,479

Significant Accounting Policies - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2018
Operating Leases
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets, net	$ 288,847,000	$ 231,662,000
Operating lease liabilities	303,443,000	241,616,000
Decrease in retained earnings	$ 3,454,831,000	$ 3,116,215,000
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	364 days	364 days	364 days
Outstanding checks in excess of funds on deposit classified as accounts payable	$ 1,300,000	$ 29,500,000
Costs of goods sold	7,304,798,000	6,894,917,000	$ 6,506,856,000
Advertising and promotional costs	30,800,000	25,200,000	12,900,000
Impairment charge on intangible assets	20,275,000	0	0
Goodwill impairment loss	0
Total distribution network costs	71,700,000	72,300,000	69,600,000
Income taxes	(95,374,000)	(159,515,000)	(107,432,000)
Contract with Customer, Liability, Current	71,500,000	70,800,000
Contract with Customer, Liability, Noncurrent	8,200,000	6,200,000
Direct shipping and handling costs [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Costs of goods sold	79,200,000	73,800,000	$ 70,600,000
Variable Interest Entity, Primary Beneficiary [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Pledged assets	0.0	127,000,000
Variable Interest Entity, Primary Beneficiary [Member] \| Recourse [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liabilities of VIE	$ 0.0	100,000,000
Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	364 days
Percentage ownership of subsidiaries included in consolidated tax return	80.00%
Maximum [Member]
Operating Leases
Lessee, Operating Lease, Option to Extend	up to 10 years
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year duration	371 days
Accounting Standards Update 2016-02 [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets, net				$ 259,900,000
Operating lease liabilities				267,300,000
Decrease in prepaid rent				1,100,000
Decrease in deferred rent liabilities				$ 8,500,000
Accounting Standards Update 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]	true
AccountingStandardsUpdate201613Member \| Cumulative Effect, Period of Adoption, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease in retained earnings		$ (400,000)

Discontinued Operations - Summarized financial information for our discontinued operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018	Feb. 07, 2019	Dec. 30, 2017
Summarized financial information for our discontinued operations
Costs of goods sold	$ 7,304,798	$ 6,894,917	$ 6,506,856
Selling, general and administrative	2,246,947	2,357,920	2,217,273
Income (loss) from discontinued operations	986	(6,323)	111,685
Net (income) loss attributable to noncontrolling interests	0	(366)	6,521
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	986	(5,957)	105,164
Assets transferred
Total current assets of discontinued operations	0	0
Operating lease right-of-use assets, net	288,847	231,662
Investments and other	366,445	327,919
Total long-term assets of discontinued operations	0	0
Liabilities transferred
Current maturities of long-term debt	109,836	109,849
Operating lease liabilities	64,716	65,349
Accrued expenses:
Total debt	515,773	622,908
Operating lease liabilities	238,727	176,267
Total long-term liabilities of discontinued operations	0	0
Redeemable noncontrolling interests	327,699	287,258	219,724		$ 465,585
Henry Schein Animal Health Business [Member]
Summarized financial information for our discontinued operations
Net sales	0	319,522	3,784,392
Costs of goods sold	0	260,097	3,100,055
Gross Profit	0	59,425	684,337
Selling, general and administrative	2,347	68,919	531,905
Operating income (loss)	(2,347)	(9,494)	152,432
Income tax expense (benefit)	(3,333)	(2,181)	48,060
Income (loss) from discontinued operations	986	(6,323)	111,685
Net (income) loss attributable to noncontrolling interests	0	366	(6,521)
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	986	(5,957)	$ 105,164
Assets transferred
Cash and cash equivalents				$ 6,815
Accounts receivable, net				432,812
Inventories, net				536,637
Prepaid expenses and other				120,546
Total current assets of discontinued operations				1,096,810
Property and equipment, net				69,790
Operating lease right-of-use assets, net				57,012
Goodwill				742,931
Other intangibles, net				205,793
Investments and other				120,518
Total long-term assets of discontinued operations				1,196,044
Total assets of discontinued operations				2,292,854
Liabilities transferred
Accounts payable				316,162
Current maturities of long-term debt				657
Operating lease liabilities				18,951
Accrued expenses:
Payroll and related				36,847
Taxes				24,060
Other				80,400
Total current liabilities of discontinued operations				477,077
Total debt				1,176,105
Deferred income taxes				17,019
Operating lease liabilities				38,668
Other liabilities				29,209
Total long-term liabilities of discontinued operations				1,261,001
Total liabilities of discontinued operations				1,738,078
Redeemable noncontrolling interests	$ 0	$ 0		$ 28,270

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 07, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off		$ 0	$ 1,120,000	$ 0
Proceeds related to Animal Health Share Sale		$ 0	$ 361,090	$ 0
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Henry Schein stockholders and the Share Sale Investors [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	37.00%
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Vets First Corp [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off	$ 1,120,000
Proceeds related to Animal Health Share Sale	$ 361,100
Noncontrolling Interest, Ownership Percentage by Parent	63.00%

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 868,182	$ 798,591
Less accumulated depreciation	(526,178)	(468,946)
Property and equipment, net	342,004	329,645
Property and equipment related depreciation expense	64,300	64,400	$ 58,100
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,297	18,030
Buildings and permanent improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 145,160	121,823
Property and equipment, average useful life (in years)	40 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 107,753	104,089
Machinery and warehouse equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 142,437	124,640
Machinery and warehouse equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	5 years
Machinery and warehouse equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 108,041	99,083
Furniture, fixtures and other [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Furniture, fixtures and other [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 344,494	$ 330,926
Computer equipment and software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Computer equipment and software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years

Goodwill and Other Intangibles, Net - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019
Goodwill [Roll Forward]
Beginning balance	$ 2,462,495	$ 2,081,029
Adjustments to goodwill: Acquisitions	26,331	388,628
Adjustments to goodwill: foreign currency translation	15,566	(7,162)
Ending balance	2,504,392	2,462,495
Health Care Distribution [Member]
Goodwill [Roll Forward]
Beginning balance	1,476,719	1,433,412
Adjustments to goodwill: Acquisitions	14,230	50,276
Adjustments to goodwill: foreign currency translation	9,888	(6,969)
Ending balance	1,500,837	1,476,719
Technology and Value-Added Services [Member]
Goodwill [Roll Forward]
Beginning balance	985,776	647,617
Adjustments to goodwill: Acquisitions	12,101	338,352
Adjustments to goodwill: foreign currency translation	5,678	(193)
Ending balance	$ 1,003,555	$ 985,776

Goodwill and Other Intangibles, Net - Other Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Other intangible assets cost	$ 887,384	$ 960,945
Other intangible assets net	479,429	572,878
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated amortization	(407,955)	(388,067)
Non-compete agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	30,993	34,553
Accumulated amortization	(11,480)	(9,327)
Net	$ 19,513	25,226
Non-compete agreements [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	5 years 1 month 6 days
Trademarks and tradenames, finite lived [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 95,382	99,314
Accumulated amortization	(50,893)	(44,134)
Net	$ 44,489	55,180
Trademarks and tradenames, finite lived [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	8 years 1 month 6 days
Customer relationships and lists [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 652,605	715,630
Accumulated amortization	(283,469)	(274,330)
Net	$ 369,136	441,300
Customer relationships and lists [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	10 years
Product development [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 94,216	85,211
Accumulated amortization	(54,451)	(42,326)
Net	$ 39,765	42,885
Product development [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	8 years 6 months
Other intangibles assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 14,188	26,237
Accumulated amortization	(7,662)	(17,950)
Net	$ 6,526	$ 8,287

Goodwill and Other Intangibles, Net - Amortization (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Goodwill and other Intangibles, Net Disclosure [Abstract]
Amortization expense related to definite-lived intangible assets	$ 105,900	$ 108,300	$ 75,300
Annual amortization expense expected for 2021	99,300
Annual amortization expense expected for 2022	85,500
Annual amortization expense expected for 2023	78,000
Annual amortization expense expected for 2024	54,800
Annual amortization expense expected for 2025	43,200
Impairment of Intangible Assets (Excluding Goodwill)	$ 20,275	$ 0	$ 0

Investments and Other (Details) - USD ($) $ in Thousands	12 Months Ended
Investments and Other (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Investments And Other [Abstract]
Investments in unconsolidated affiliates	$ 169,382	$ 164,659
Non-current deferred foreign, state and local income taxes	42,594	23,625
Notes receivable	34,760	43,544
Capitalized costs for internally generated software for resale	47,650	42,445
Security deposits	1,752	534
Acquisition related indemnification	49,401	38,464
Other long-term assets	20,906	14,648
Total	366,445	327,919
Amortization of other long-term assets	$ 15,300	$ 12,300	$ 10,200

Investments and Other - Long-term notes receivable (Details) - Financing Receivable [Member]	12 Months Ended
	Dec. 26, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Latest maturity date of varying installments of long-term notes receivable	Sep. 30, 2027
Minimum [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long-term notes receivable interest rate (as a percent)	1.00%
Maximum [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long-term notes receivable interest rate (as a percent)	14.00%

Debt - Bank Credit Lines (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Line of Credit Facility [Line Items]
Bank credit lines	$ 73,366	$ 23,975
Revolving credit facility [Member]
Line of Credit Facility [Line Items]
Bank credit lines	0	0
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines	$ 73,366	$ 23,975

Debt - Revolving Credit Agreement 364 Day Credit Agreement and Other Short-Term Credit Lines - Narrative (Details) - USD ($)		4 Months Ended
	Apr. 17, 2020	Apr. 18, 2017	Dec. 26, 2020	Dec. 28, 2019
Line of Credit Facility [Line Items]
Bank credit lines			$ 73,366,000	$ 23,975,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Bank credit lines			0	0
Revolving credit facility maturing in April 2022 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date		Apr. 18, 2017
Line of Credit Facility, Maximum Borrowing Capacity		$ 750,000,000
Line of credit facility, amount outstanding			0	0
Outstanding letters of credit provided to third parties			9,500,000	9,600,000
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines			$ 73,366,000	$ 23,975,000
Weighted average interest rate on borrowings under credit lines at period end (as a percent)			4.14%	3.45%
Three Hundred Sixty Four Day Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date	Apr. 17, 2020
Line of Credit Facility, Maximum Borrowing Capacity	$ 700,000,000		$ 700,000,000
Revolving credit facility expiration date	Apr. 16, 2021
Line of Credit Facility, Expiration Period	364 days
Line of Credit Facility, Description	The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At December 26, 2020, the interest rate on this facility was 2.50%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness
Line of credit facility, amount outstanding			0
Additional borrowing capacity			$ 200,000,000
Weighted average interest rate on borrowings under credit lines at period end (as a percent)	2.50%

Debt - Committed Loan Associated with Animal Health Spin-off - Narrative (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Line of Credit Facility [Line Items]
Short-term borrowings	$ 73,366	$ 23,975

Debt - Long-term Debt (Details) - USD ($) $ in Thousands	12 Months Ended
Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Total Long-term debt	$ 625,609	$ 732,757
Less current maturities	(109,836)	(109,849)
Finance lease obligations	5,961	5,394
Total debt	515,773	622,908
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Total Long-term debt	613,498	621,274
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Total Long-term debt	0	100,000
Notes payable due 2025 at a weighted average interest rate of 3.1% [Member]
Debt Instrument [Line Items]
Total Long-term debt	$ 1,554	0
Debt instrument, interest rate, stated percentage	3.10%
Debt Instrument, Maturity Date, Description	2025
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member]
Debt Instrument [Line Items]
Total Long-term debt	$ 4,596	$ 6,089
Debt Instrument, Maturity Date, Description	2023
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.62%	2.56%
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.27%	10.50%

Debt - Private Placement Facilities - Narrative (Details) - Private placement facilities [Member] $ in Billions	12 Months Ended
	Dec. 26, 2020 USD ($)
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1
Debt Instrument, Maturity Date	Jun. 23, 2023
Debt Instrument, Covenant Description	On June 23, 2020, we amended the private placement facilities to, among other things, (i) temporarily modify the financial covenant from being based on total leverage ratio to net leverage ratio until March 31, 2021, (ii) increase the maximum maintenance leverage ratio through March 31, 2021, but with a 1.00% interest rate increase on the outstanding notes if the net leverage ratio exceeds 3.0x, which will remain in effect until we deliver financials for a four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conforming to the Credit Agreement, dated as of April 18, 2017, as amended.
Increase in maximum maintenance leverage ratio	1.00%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years
Average term of issuances under private placement facilities	12 years
Net leverage ratio	3.0

Debt - Private Placement Facility Borrowings (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 20, 2016	Dec. 26, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Less: Deferred debt issuance costs		$ (800)
Long-term Debt and finance Lease Obligations, Including Current Maturities		625,609	$ 732,757
Private placement facilities [Member]
Debt Instrument [Line Items]
Less: Deferred debt issuance costs		(788)
Long-term Debt and finance Lease Obligations, Including Current Maturities		$ 613,498	$ 621,274
Due date		Jun. 23, 2023
Debt Conversion, Original Debt, Amount		$ 100,000
Debt Conversion, Original Debt, Due Date of Debt		Sep. 02, 2020
Debt Conversion, Original Debt, Interest Rate of Debt		3.79%
Debt Conversion, Converted Instrument, Type		10-year borrowing
Debt Conversion, Converted Instrument, Rate		2.35%
Debt Conversion, Converted Instrument, Expiration or Due Date		Sep. 02, 2030
Private placement facilities [Member] \| Private placement facilities maturing in January 2022 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jan. 20, 2012
Amount of borrowing outstanding		$ 14,286
Borrowing Rate		3.09%
Due date		Jan. 20, 2022
Private placement facility, repayment frequency		Annual
Private placement facility, annual payment	$ 7,100
Debt Instrument, Date of First Required Payment		Jan. 20, 2016
Private placement facilities [Member] \| Private placement facilities maturing in January 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jan. 20, 2012
Amount of borrowing outstanding		$ 50,000
Borrowing Rate		3.45%
Due date		Jan. 20, 2024
Private placement facilities [Member] \| Private placement facilities maturing in December 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing		Dec. 24, 2012
Amount of borrowing outstanding		$ 50,000
Borrowing Rate		3.00%
Due date		Dec. 24, 2024
Private placement facilities [Member] \| Private placement facilities maturing in June 2021 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jun. 02, 2014
Amount of borrowing outstanding		$ 100,000
Borrowing Rate		3.19%
Due date		Jun. 02, 2021
Private placement facilities [Member] \| Private Placement facilities maturing in June 2027 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jun. 16, 2017
Amount of borrowing outstanding		$ 100,000
Borrowing Rate		3.42%
Due date		Jun. 16, 2027
Private placement facilities [Member] \| Private Placement Facilities maturing in September 2029 [Member]
Debt Instrument [Line Items]
Date of borrowing		Sep. 15, 2017
Amount of borrowing outstanding		$ 100,000
Borrowing Rate		3.52%
Due date		Sep. 15, 2029
Private placement facilities [Member] \| Private Placement facilities maturing in January 2028 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jan. 02, 2018
Amount of borrowing outstanding		$ 100,000
Borrowing Rate		3.32%
Due date		Jan. 02, 2028
Private placement facilities [Member] \| Private placement facilities maturing in September 2030 [Member]
Debt Instrument [Line Items]
Date of borrowing		Sep. 02, 2020
Amount of borrowing outstanding		$ 100,000
Borrowing Rate		2.35%
Due date		Sep. 02, 2030

Debt - U.S. Trade Accounts Receivable Securitization - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Long-term Debt and finance Lease Obligations, Including Current Maturities	$ 625,609	$ 732,757
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Apr. 29, 2022
Line of Credit Facility, Maximum Borrowing Capacity	$ 350,000
Long-term Debt and finance Lease Obligations, Including Current Maturities	$ 0	$ 100,000
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.45%
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.25%
U.S. trade accounts receivable securitization [Member] \| Extended Maturity [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	Jun. 12, 2023
U.S. trade accounts receivable securitization [Member] \| Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Variable Rate Basis At Period End	0.22%	1.90%
Debt instrument, basis spread on variable rate	0.95%	0.75%
Debt instrument, interest rate at period end	1.17%	2.65%

Debt - Maturities (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Maturities of Long-term Debt [Abstract]
2021	$ 109,836
2022	11,607
2023	1,916
2024	100,303
2025	1,839
Thereafter	400,108
Total Long-term debt	625,609	$ 732,757
Debt Instrument [Line Items]
Debt Issuance Costs, Gross	800
Private Placement Facilities [Member]
Maturities of Long-term Debt [Abstract]
Total Long-term debt	613,498	$ 621,274
Debt Instrument [Line Items]
Debt Issuance Costs, Gross	$ 788

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Millions	Dec. 26, 2020	Dec. 28, 2019
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Description	We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment.
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Lessee, Operating Lease, Lease Not yet Commenced, Description	for buildings and vehicles
Operating lease assets, Lease not yet commenced	$ 13.5
Operating Lease, Right-of-Use Asset, Amortization Expense including Operating lease credits	$ 0.6	$ 0.6
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	1 year
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	2 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	16 years
Lessee, Operating Lease, Option to Extend	up to 10 years
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	10 years

Leases - Components of lease expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019
Leases [Abstract]
Operating lease cost	$ 86,800	$ 88,246
Finance lease cost:
Amortization of right-of-use assets	2,209	1,154
Interest on lease liabilities	115	131
Finance lease cost	$ 2,324	$ 1,285

Leases - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Operating Leases
Operating lease right-of-use assets, net	$ 288,847	$ 231,662
Current operating lease liabilities	64,716	65,349
Non-current operating lease liabilities	238,727	176,267
Total operating lease liabilities	303,443	241,616
Finance leases
Property and equipment, at cost	10,683	10,268
Accumulated depreciation	(4,277)	(4,581)
Property and equipment, net of accumulated depreciation	6,406	5,687
Current maturities of long-term debt	2,420	1,736
Long-term debt	3,541	3,658
Total finance lease liabilities	$ 5,961	$ 5,394
Weighted Average Remaining Lease Term, in years, Operating Lease	7 years 6 months	5 years 6 months
Weighted Average Remaining Lease Term, in years, Finance Lease	4 years 3 months 18 days	5 years
Weighted Average Discount Rate, Percent, Operating Lease	2.80%	3.40%
Weighted Average Discount Rate, Percent, Finance Lease	1.90%	2.20%

Leases - Supplemental cash flow information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 76,985	$ 79,699
Operating cash flows for finance leases	101	99
Financing cash flows for finance leases	2,148	1,413
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	120,148	297,800
Finance leases	$ 2,947	$ 2,940

Leases - Maturities of lease liabilities (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Operating Leases
2021	$ 71,801
2022	58,049
2023	40,670
2024	28,899
2025	26,147
Thereafter	110,228
Total future lease payments	335,794
Less imputed interest	(32,351)
Total operating lease liabilities	303,443	$ 241,616
Finance Leases
2021	2,503
2022	1,542
2023	596
2024	327
2025	305
Thereafter	920
Total future lease payments	6,193
Less imputed interest	(232)
Total finance lease liabilities	$ 5,961	$ 5,394

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 287,258	$ 219,724	$ 465,585
Decrease in redeemable noncontrolling interests due to redemptions	(17,241)	(2,270)	(287,767)
Increase in redeemable noncontrolling interests due to business acquisitions	28,387	74,865	4,655
Net income attributable to redeemable noncontrolling interests	13,363	14,838	15,327
Dividends declared	(12,631)	(10,264)	(8,206)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(4,279)	(2,335)	(11,330)
Change in fair value of redeemable securities	32,842		41,460
Change in fair value of redeemable securities		(7,300)
Balance, end of period	$ 327,699	$ 287,258	$ 219,724

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (24,617)	$ (20,338)	$ (18,595)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	235	(531)	(426)
Attributable to Henry Schein, Inc.:
Foreign currency translation gain (loss)	(76,565)	(143,172)	(234,799)
Unrealized gain (loss) from foreign currency hedging activities	(11,488)	(4,032)	(156)
Unrealized investment gain (loss)	1	6	(6)
Pension adjustment gain (loss)	(20,032)	(20,175)	(13,810)
Accumulated other comprehensive income (loss)	(108,084)	(167,373)	(248,771)
Total Accumulated other comprehensive income (loss)	(132,466)	(188,242)	(267,792)
Components of comprehensive income [Abstract]
Net income	419,423	719,138	562,126
Foreign currency translation gain (loss)	63,094	(4,070)	(136,356)
Tax effect	0	0	0
Foreign currency translation gain (loss)	63,094	(4,070)	(136,356)
Unrealized gain (loss) from foreign currency hedging activities	(10,224)	(4,911)	1,022
Tax effect	2,768	1,035	(396)
Unrealized gain (loss) from foreign currency hedging activities	(7,456)	(3,876)	626
Unrealized investment gain (loss)	(6)	14	(3)
Tax effect	1	(2)	0
Unrealized investment gain (loss)	(5)	12	(3)
Pension adjustment gain (loss)	533	7,730	(4,212)
Tax effect	676	1,806	(1,179)
Pension adjustment gain (loss)	(143)	5,924	(3,033)
Comprehensive income	$ 475,199	$ 705,280	$ 429,426

Comprehensive Income - Foreign Currency Translation Gain (Loss) Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation gain (loss)	$ 63,094	$ (4,070)	$ (136,356)

Comprehensive Income - Total Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income (loss) attributable to Henry Schein, Inc.	$ 463,083	$ 682,724	$ 417,177
Comprehensive income (loss) attributable to noncontrolling interests	3,032	9,827	3,432
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	9,084	12,729	8,817
Comprehensive income (loss)	$ 475,199	$ 705,280	$ 429,426

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 327,699	$ 287,258	$ 219,724	$ 465,585
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	699,000	756,700
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps	1,565
Fair value, measurements, recurring [Member]
Assets [Abstract]
Derivative contracts - assets	1,868	567
Total assets	3,433	567
Liabilities [Abstract]
Derivative contracts - liabilities	11,765	5,795
Total liabilities	11,765	5,795
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	327,699	287,258
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps	1,565
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Derivative contracts - assets	1,868	567
Total assets	3,433	567
Liabilities [Abstract]
Derivative contracts - liabilities	11,765	5,795
Total liabilities	11,765	5,795
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 327,699	$ 287,258

Business Acquisitions and Divestitures (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Business Acquisition [Line Items]
Business acquisition allocated, goodwill	$ 2,504,392				$ 2,462,495				$ 2,504,392	$ 2,462,495	$ 2,081,029
Pretax gain on sale of equity investments	1,572	$ 0	$ 0	$ 0	186,769	$ 0	$ 0	$ 0	1,572	186,769	0
Income taxes									95,374	159,515	107,432
Equity in earnings of affiliates									12,344	17,900	21,037
Proceeds from sale of equity investment									14,020	307,251	1,000
Business Acquisition, Transaction Costs	5,900				4,500				5,900	4,500	7,300
Net sales	3,165,725	$ 2,840,146	$ 1,684,399	$ 2,428,871	2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	10,119,141	9,985,803	9,417,603
Hu-Friedy Mfg. Co., LLC [Member]
Business Acquisition [Line Items]
Pretax gain on sale of equity investments					250,200
Income taxes					63,400
Equity in earnings of affiliates										6,000	10,400
Proceeds from sale of equity investment	2,100
Animal Health [Member]
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	100				23,600				100	23,600	38,900
Technology and Value-Added Services [Member]
Business Acquisition [Line Items]
Business acquisition allocated, goodwill	1,003,555				$ 985,776				1,003,555	985,776	647,617
Income taxes									24,168	30,134	53,772
Net sales									514,258	$ 515,085	$ 408,439
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses									57,800
Net assets	32,800								32,800
Intangible Assets	36,900								36,900
Business acquisition allocated, goodwill	$ 23,900								23,900
Noncontrolling Interest, Increase from Business Combination									$ 26,400

Plans of Restructuring (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax	$ 4,380	$ 6,992	$ 15,934	$ 4,787	$ (1,059)	$ (802)	$ 11,925	$ 4,641	$ 32,093	$ 14,705	$ 54,367
Employee severance pay and benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax									25,855	13,741	50,197
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, pre-tax									$ 5,878	$ 937	$ 3,153
Strategic Plan, 2018 to 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent									4.00%

Plans of Restructuring - Restructuring Reserve Roll Forward by Expense and Segment (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				$ 13,810				$ 31,725	$ 13,810	$ 31,725	$ 4,426
Provision	$ 4,380	$ 6,992	$ 15,934	4,787	$ (1,059)	$ (802)	$ 11,925	4,641	32,093	14,705	54,367
Payments and other adjustments									(32,790)	(32,620)	(27,068)
Restructuring Reserve, ending balance	13,113				13,810				13,113	13,810	31,725
Health Care Distribution [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				13,373				30,291	13,373	30,291	4,426
Provision									30,935	13,935	50,824
Payments and other adjustments									(31,484)	(30,853)	(24,959)
Restructuring Reserve, ending balance	12,824				13,373				12,824	13,373	30,291
Technology and Value-Added Services [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				437				1,434	437	1,434	0
Provision									1,158	770	3,543
Payments and other adjustments									(1,306)	(1,767)	(2,109)
Restructuring Reserve, ending balance	289				437				289	437	1,434
Severance costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				12,911				29,964	12,911	29,964	3,087
Provision									25,855	13,741	50,197
Payments and other adjustments									(26,152)	(30,794)	(23,320)
Restructuring Reserve, ending balance	12,614				12,911				12,614	12,911	29,964
Facility closing costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				826				1,603	826	1,603	1,315
Provision									5,878	937	3,153
Payments and other adjustments									(6,309)	(1,714)	(2,865)
Restructuring Reserve, ending balance	395				826				395	826	1,603
Other [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance				$ 73				$ 158	73	158	24
Provision									360	27	1,017
Payments and other adjustments									(329)	(112)	(883)
Restructuring Reserve, ending balance	$ 104				$ 73				$ 104	$ 73	$ 158

Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
Earnings Per Share (Details) - shares shares in Thousands	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Weighted-average common shares outstanding:
Basic (in shares)	142,504	147,817	152,656
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units (in shares)	900	1,440	1,051
Diluted (in shares)	143,404	149,257	153,707

Income Taxes - Income before Taxes and Equity in Earnings of Affiliates and Provisions for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Income before equity method investments, income taxes and loss on sale of equity investment [Abstract]
Domestic	$ 430,838	$ 507,003	$ 405,289
Foreign	69,057	173,304	131,547
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests	$ 499,895	$ 680,307	$ 536,836

Income Taxes - Provisions for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Current income tax expense:
U.S. Federal	$ 82,912	$ 93,418	$ 71,854
State and local	24,640	28,150	22,533
Foreign	40,799	42,004	38,433
Total current	148,351	163,572	132,820
Deferred income tax expense (benefit):
U.S. Federal	(18,032)	5,633	206
State and local	(4,889)	1,597	(1,622)
Foreign	(30,056)	(11,287)	(23,972)
Total deferred	(52,977)	(4,057)	(25,388)
Total income tax provision	$ 95,374	$ 159,515	$ 107,432

Income Taxes - Deferred Income Tax Asset (Liabilty) (Details) - USD ($) $ in Thousands	Dec. 26, 2020	Dec. 28, 2019
Deferred income tax asset:
Investment in partnerships		$ 1,420
Investment in partnerships	$ (6,294)
Net operating losses and other carryforwards	64,297	43,663
Inventory, premium coupon redemptions and accounts receivable valuation allowances	56,668	23,808
Stock-based compensation	4,858	14,075
Uniform capitalization adjustment to inventories	6,895	7,259
Operating lease right of use asset	74,674	56,780
Other asset	49,260	33,311
Total deferred income tax asset	250,358	180,316
Valuation allowance for non-current deferred tax assets	(40,496)	(20,699)
Net deferred income tax asset	209,862	159,617
Deferred income tax liability
Intangibles amortization	(118,165)	(135,754)
Operating lease liability	(71,343)	(54,672)
Property and equipment	(7,820)	(10,555)
Total deferred tax liability	(197,328)	(200,981)
Net deferred income tax asset (liability)	$ 12,534	$ (41,364)

Income Taxes - Operating Loss Carryforwards (Details) $ in Millions	12 Months Ended
	Dec. 26, 2020 USD ($)
Foreign tax authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards subject to amortization	$ 200.5
Net operating loss carryforwards not subject to expiration	$ 199.3
Foreign tax authority [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2024
Foreign tax authority [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2040
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards subject to amortization	$ 31.6
Net operating loss carryforwards not subject to expiration	$ 10.6
State and Local Jurisdiction [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2024
State and Local Jurisdiction [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2040
Federal tax authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards subject to amortization	$ 29.8
Federal tax authority [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2024
Federal tax authority [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforward expiration year	2040

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 30, 2017	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax provision at federal statutory rate		$ 104,977	$ 142,865	$ 112,735
State income tax provision, net of federal income tax effect		13,015	16,539	15,872
Foreign income tax benefit		(428)	(4,580)	(2,558)
Pass through noncontrolling interest		(2,681)	(3,931)	(2,700)
Valuation allowance		659	(79)	2,017
Unrecognized tax benefits and audit settlements		(17,722)	3,671	2,126
Interest expense related to loans		(11,098)	(5,498)	(11,700)
Excess tax benefits related to stock compensation		778	(86)	(1,008)
Transition tax on deemed repatriation of foreign earnings	$ 140,000	0	0	(10,000)
Revaluation of deferred tax assets and liabilities	$ 3,000	0	0	(1,676)
Tax on global intangible low-taxed income ("GILTI")		2,365	3,917	7,599
Tax benefit related to legal entity reorganization outside the U.S.		(5,823)	0	(13,852)
Tax charge related to reorganization of legal entities related to forming Henry Schein One		0	0	3,914
Tax charge related to reorganization of legal entities completed in preparation for the Animal Health spin-off		0	(1,333)	3,135
Other		11,332	8,030	3,528
Total income tax provision		$ 95,374	$ 159,515	$ 107,432

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of period	$ 91,100	$ 77,800	$ 83,200
Additions based on current year tax positions	4,900	4,900	5,000
Additions based on prior year tax positions	7,900	17,300	9,400
Reductions based on prior year tax positions	(1,000)	(1,000)	(1,600)
Reductions resulting from settlements with taxing authorities	(18,600)	(4,200)	(1,600)
Reductions resulting from lapse in statutes of limitations	(14,300)	(3,700)	(16,600)
Balance, end of period	$ 70,000	$ 91,100	$ 77,800

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 30, 2017	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Income Taxes [Abstract]
Effective tax rate (in hundredths)		19.10%	23.40%	20.00%
Allowable business interest deduction rate before modification to Section 163(j)		30.00%
Allowable business interest deduction rate after modification to Section 163(j)		50.00%
Effect of Tax Cuts and Jobs Act [Abstract]
Corporate tax rate	35.00%
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent	0.21
Provision for (benefit from) transitional tax	$ 140,000,000.0	$ 0	$ 0	$ (10,000,000)
Revaluation of deferred tax assets and liabilities	3,000,000.0	0	0	(1,676,000)
Tax on global intangible low-taxed income ("GILTI")		2,365,000	3,917,000	7,599,000
Unrecognized tax benefits		84,000,000.0
Unrecognized tax benefits that would affect the effective tax rate if recognized		70,100,000
Total interest		14,000,000.0	18,000,000.0
Total penalties	$ 0	0	0
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority		(3,300,000)	2,200,000	$ 3,600,000
Accrued taxes [Member]
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current		9,900,000	9,900,000
Other Liabilities [Member]
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current		$ 74,500,000	$ 94,900,000

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Dec. 26, 2020	Dec. 28, 2019
Top customer concentration risk [Member] \| Sales revenue, net [Member] \| Any single customer [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)		2.00%
Top customer concentration risk [Member] \| Sales revenue, net [Member] \| Any two customers [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	3.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Top ten health care distribution suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	30.00%	31.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Single largest supplier [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	4.00%	6.00%

Derivatives and Hedging Activities (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 26, 2020 USD ($)	Dec. 28, 2019 USD ($)	Dec. 26, 2020 EUR (€)	Dec. 26, 2020 USD ($)	Mar. 20, 2020 USD ($)
Derivative [Line Items]
Maximum duration of foreign currency forward contracts	18 months
SERP and DCP [Member]
Derivative [Line Items]
Fair value increase in SERP and DCP liabilities	$ 10.6
Forward Contracts [Member]
Derivative [Line Items]
Objectives for Using Net Investment Hedging Instruments	During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges.
Description of Net Investments Hedged	These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates.
Description of Location of Gain (Loss) on Net Investment Hedges in Financial Statements	Accumulated other comprehensive loss
Total Return Swap [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount				$ 67.6	$ 43.4
Derivative, Description of Objective	we entered into a total return swap for the purpose of economically hedging our unfunded non-qualified SERP and DCP. This swap will offset changes in our SERP and DCP liabilities.
Derivative, Inception Date	Mar. 20, 2020
Derivative, Variable Interest Rate			0.53%	0.53%
Gain on derivatives net of transaction costs	$ 21.2
Total Return Swap [Member] \| London Interbank Offered Rate (LIBOR) Swap Rate [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Variable Interest Rate			0.15%	0.15%
Total Return Swap [Member] \| Base Rate [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Basis Spread on Variable Rate			0.38%	0.38%
Net Investment Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount \| €			€ 200
Derivative, Maturity Dates	Nov. 16, 2023
Interest savings from net investment hedge	$ 4.7	$ 0.6

Revenue from Contracts with Customers - Disaggregation of Net sales (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Disaggregation of Revenue [Abstract]
Net sales	$ 3,165,725	$ 2,840,146	$ 1,684,399	$ 2,428,871	$ 2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	$ 10,119,141	$ 9,985,803	$ 9,417,603
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									7,433,021	7,255,298
International [Member]
Disaggregation of Revenue [Abstract]
Net sales									2,686,120	2,730,505
Total excluding Corporate TSA revenues
Disaggregation of Revenue [Abstract]
Net sales									10,043,868	9,904,536	9,417,603
Total excluding Corporate TSA revenues \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									7,433,021	7,251,200
Total excluding Corporate TSA revenues \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									2,610,847	2,653,336
Healthcare Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales									9,529,610	9,389,451	9,009,164
Healthcare Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									6,986,191	6,805,883
Healthcare Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									2,543,419	2,583,568
Healthcare Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales									5,912,593	6,415,865	6,347,998
Healthcare Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									3,471,521	3,911,746
Healthcare Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									2,441,072	2,504,119
Healthcare Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales									3,617,017	2,973,586	2,661,166
Healthcare Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									3,514,670	2,894,137
Healthcare Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									102,347	79,449
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales									514,258	515,085	408,439
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									446,830	445,317
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									67,428	69,768
Corporate TSA [Member]
Disaggregation of Revenue [Abstract]
Net sales									75,273	81,267	$ 0
Corporate TSA [Member] \| Animal Health [Member]
Disaggregation of Revenue [Abstract]
Net sales									75,273	81,267
Corporate TSA [Member] \| Animal Health [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales									0	4,098
Corporate TSA [Member] \| Animal Health [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales									$ 75,273	$ 77,169

Segment and Geographic Data (Details) $ in Thousands	3 Months Ended								12 Months Ended
Segment and Geographic Data (Details) $ in Thousands	Dec. 26, 2020 USD ($) countries	Sep. 26, 2020 USD ($)	Jun. 27, 2020 USD ($)	Mar. 28, 2020 USD ($)	Dec. 28, 2019 USD ($)	Sep. 28, 2019 USD ($)	Jun. 29, 2019 USD ($)	Mar. 30, 2019 USD ($)	Dec. 26, 2020 USD ($) number countries	Dec. 28, 2019 USD ($)	Dec. 29, 2018 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| number									2
Number of countries served globally \| countries	31								31
Net sales	$ 3,165,725	$ 2,840,146	$ 1,684,399	$ 2,428,871	$ 2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	$ 10,119,141	$ 9,985,803	$ 9,417,603
Operating income	181,200	$ 187,671	$ (7,433)	$ 173,865	196,334	$ 187,198	$ 162,288	$ 172,441	535,303	718,261	600,619
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment									499,895	680,307	536,836
Depreciation and amortization									185,538	184,942	143,630
Interest income									9,842	15,757	15,491
Interest expense									41,377	50,792	76,016
Income taxes									95,374	159,515	107,432
Purchases of fixed assets									48,829	76,219	71,283
Total assets	7,772,532				7,151,101				7,772,532	7,151,101	8,500,527
Discontinued operations [Member]
Segment Reporting Information [Line Items]
Total assets	0				0				0	0	2,216,673
Total excluding Corporate TSA revenues
Segment Reporting Information [Line Items]
Net sales									10,043,868	9,904,536	9,417,603
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales									9,529,610	9,389,451	9,009,164
Operating income									436,173	591,404	490,988
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment									400,343	553,181	429,429
Depreciation and amortization									142,712	146,960	122,767
Interest income									9,736	15,352	15,106
Interest expense									41,307	50,666	76,006
Income taxes									71,206	129,381	53,660
Purchases of fixed assets									43,511	69,095	68,577
Total assets	6,503,089				5,821,468				6,503,089	5,821,468	5,288,662
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales									5,912,593	6,415,865	6,347,998
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales									3,617,017	2,973,586	2,661,166
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales									514,258	515,085	408,439
Operating income									99,130	126,857	109,631
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment									99,552	127,126	107,407
Depreciation and amortization									42,826	37,982	20,863
Interest income									106	405	385
Interest expense									70	126	10
Income taxes									24,168	30,134	53,772
Purchases of fixed assets									5,318	7,124	2,706
Total assets	$ 1,269,443				$ 1,329,633				1,269,443	1,329,633	995,192
Corporate TSA [Member]
Segment Reporting Information [Line Items]
Net sales									75,273	81,267	$ 0
Corporate TSA [Member] \| Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales									$ 75,273	$ 81,267

Segment and Geographic Data - Net Sales and Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 3,165,725	$ 2,840,146	$ 1,684,399	$ 2,428,871	$ 2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	$ 10,119,141	$ 9,985,803	$ 9,417,603
Long-Lived Assets	3,614,672				3,596,680				3,614,672	3,596,680	2,771,281
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									7,090,206	6,876,194	6,411,558
Long-Lived Assets	2,362,823				2,400,733				$ 2,362,823	2,400,733	1,753,697
United States [Member] \| Geographic Concentration Risk [Member] \| Sales revenue, net [Member] \| Minimum [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage (as a percent)									10.00%
Locations other than the United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									$ 3,028,935	3,109,609	3,006,045
Long-Lived Assets	$ 1,251,849				$ 1,195,947				$ 1,251,849	$ 1,195,947	$ 1,017,584

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Employee Benefit Plans - Stock-Based Compensation (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 26, 2020	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax share-based compensation expense		$ 8,800,000	$ 44,900,000	$ 32,600,000
After-tax share-based compensation expense		7,100,000	34,400,000	25,300,000
Excess tax benefits		$ 0	$ 0	$ 0
Liability for cash settlement stock-based compensation awards	$ 800,000
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)		$ 60.23	$ 56.83	$ 71.38
Total unrecognized compensation cost related to non-vested awards	$ 42,200,000	$ 42,200,000
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)		2 years 3 months 18 days
Total cash received as a result of stock options exercises		$ 0	$ 34,000	$ 3,076,000
Stock option exercises tax benefits		$ 0	$ 0
Long-term Incentive Program [Member] \| Restricted stock/units [Member] \| Henry Schein Animal Health Business [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	1.2633
Decrease in price per share		$ (1.2633)

Employee Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 26, 2020	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Employee and director stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)		0	3,000	155,000
Granted (in shares)		0	0	0
Exercised (in shares)		0	(3,000)	(152,000)
Forfeited (in shares)		0	0	0
Outstanding at end of period (in shares)	0	0	0	3,000
Ending balance, options exercisable (in shares)	0	0		3,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)		$ 0	$ 17.22	$ 29.65
Granted (in dollars per share)		0		0
Exercised (in dollars per share)		0		29.81
Forfeited (in dollars per share)		0		0
Outstanding at end of period (in dollars per share)	$ 0	0	$ 0	17.22
Ending balance, options exercisable (in dollars per share)	$ 0	$ 0		$ 17.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock option outstanding aggregate intrinsic value as of period end	$ 0	$ 0	$ 0	$ 121
Stock option exercisable aggregate intrinsic value as of period end	$ 0	$ 0	$ 0	$ 121
Restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Intrinsic value (in dollars per share)	$ 61.49	$ 61.49	$ 64.31	$ 76.48
Time-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares)		1,417,000
Granted (in shares)		391,000
Vested (in shares)		(298,000)
Forfeited (in shares)		(51,000)
Ending balance outstanding (in shares)	1,459,000	1,459,000	1,417,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)		$ 58.72
Granted (in dollars per share)		60.19
Vested (in dollars per share)		65.91
Forfeited (in dollars per share)		59.71
Ending balance outstanding (in dollars per share)	$ 57.61	57.61	$ 58.72
Intrinsic value (in dollars per share)	$ 65.83	$ 65.83
Performance-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares)		1,459,000
Granted (in Shares)		(954,000)
Vested (in shares)		(327,000)
Forfeited (in shares)		(42,000)
Ending balance outstanding (in shares)	136,000	136,000	1,459,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)		$ 61.41
Granted (in dollars per share)		56.52
Vested (in dollars per share)		67.48
Forfeited (in dollars per share)		57.82
Ending balance outstanding (in dollars per share)	$ 53.52	53.52	$ 61.41
Intrinsic value (in dollars per share)	65.83	65.83
Long-term Incentive Program [Member] \| Employee and director stock options [Member] \| Henry Schein Animal Health Business [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Ending balance, options exercisable (in shares)			0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)		0	$ 13.63
Granted (in dollars per share)		0	0
Exercised (in dollars per share)		0	13.63
Forfeited (in dollars per share)		0	0
Outstanding at end of period (in dollars per share)	$ 0	$ 0	0	$ 13.63
Ending balance, options exercisable (in dollars per share)			$ 0
2020 (formerly known as 2013) Stock Incentive Plan, as amended [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	65,243,000	65,243,000
Shares available to be granted (in shares)	5,812,000	5,812,000
2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	1,893,000	1,893,000
Shares available to be granted (in shares)	265,000	265,000
2015 Non-Employee Director Stock Incentive Plan [Member] \| Restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	12 months

Employee Benefit Plans - Other Employee Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Management [Member] \| Deferred compensation bonus and commission plan [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation plan fair market value amount charged (credited) to operations	$ 7.8	$ 8.3	$ (2.3)
Qualified 401K plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ (19.9)	(34.9)	(35.0)
Qualified 401K plan [Member] \| Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum matching contributions as a percentage of participants' contributions (as a percent)	100.00%
Maximum participants' contributions as a percentage of their base compensation (as a percent)	7.00%
Allowable maximum percentage of contributions allocated to Henry Schein Stock Fund (as a percent)	20.00%
Supplemental executive retirement plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ (2.8)	$ (4.0)	$ (0.4)

Commitments and Contingencies - Unrecorded Unconditional Purchase Obligation (Details) $ in Thousands	Dec. 26, 2020 USD ($)
Unrecorded Unconditional Purchase Obligation [Abstract]
2021	$ 208,200
2022	110,800
2023	0
2024	0
2025	0
Thereafter	0
Total minimum inventory purchase commitment payments	$ 319,000

Commitments and Contingencies - Other Commitments (Details) $ in Thousands	12 Months Ended
	Dec. 26, 2020 USD ($)
Employment, consulting and non-compete agreements [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
2021	$ 16,900
2022	6,800
2023	1,000
2024	900
2025	900
Thereafter	900
Life-time consulting agreement [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
Current compensation paid under lifetime consulting agreement	400
Amount of increase effective every fifth year on lifetime consulting agreement	$ 25

Commitments and Contingencies - Litigation (Details)	3 Months Ended								12 Months Ended
Commitments and Contingencies - Litigation (Details)	Dec. 26, 2020 USD ($) number	Sep. 26, 2020 USD ($)	Jun. 27, 2020 USD ($)	Mar. 28, 2020 USD ($)	Dec. 28, 2019 USD ($)	Sep. 28, 2019 USD ($)	Jun. 29, 2019 USD ($)	Mar. 30, 2019 USD ($)	Dec. 26, 2020 USD ($) number	Dec. 28, 2019 USD ($)	Dec. 29, 2018 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Net sales	$ 3,165,725,000	$ 2,840,146,000	$ 1,684,399,000	$ 2,428,871,000	$ 2,668,941,000	$ 2,508,767,000	$ 2,447,827,000	$ 2,360,268,000	$ 10,119,141,000	$ 9,985,803,000	$ 9,417,603,000
Loss Contingency, Management's Assessment and Process									As of December 26, 2020, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.
Archer and White Sales, Inc. v. collectively, the Danaher Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									August 31, 2012
Loss Contingency, Name of Defendant									Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”)
Loss Contingency, Name of Plaintiff									Archer and White Sales, Inc. (“Archer”)
Loss Contingency, Allegations									Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights
Archer filed amended complaint adding Patterson and Benco as Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									August 1, 2017
Loss Contingency, Name of Defendant									Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”)
Loss Contingency, Name of Plaintiff									Archer
Loss Contingency, Allegations									alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer.
Archer filed second amended complaint under seal [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									October 30, 2017
Loss Contingency, Name of Plaintiff									Archer
Loss Contingency, Allegations									to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.
The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									May 29, 2018
Loss Contingency, Name of Defendant									Henry Schein Medical Systems, Inc. and others as defendants
Loss Contingency, Name of Plaintiff									The County of Summit, Ohio et al
Loss Contingency, Pending Claims, Number \| number	150								150
Loss Contingency, Allegations									Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs.
Donation amount to Pain Management Education Foundation									$ 1,000,000
Litigation Settlement, Amount Awarded to Other Party									$ 250,000
Loss Contingency Settlement Agreement Terms									On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation and paid $250,000 of Summit County’s expenses, as described in our prior filings with the SEC.
Actions consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Name of Defendant									Henry Schein and/or one or more of its affiliated companies
Loss Contingency, Allegations									allege claims similar to those alleged in the County of Summit Action.
Actions consolidated in the MultiDistrict Litigation [Member] \| Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage									0.01%
Actions consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Net sales									$ 10,100,000,000
City of Hollywood Police Officers Retirement System V. Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									September 30, 2019
Loss Contingency, Name of Defendant									Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively)
Loss Contingency, Name of Plaintiff									City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated
Loss Contingency, Allegations									The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading
Frank Finazzo against various present and former directors and officers of Henry Schein [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date									November 15, 2019
Loss Contingency, Name of Defendant									The named defendants in the action were Stanley M. Bergman, Steven Paladino, Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph L. Herring, Donald J. Kabat, Kurt Kuehn, Philip A. Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews, Mark E. Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares, and Louis W. Sullivan, with Henry Schein named as a nominal defendant.
Loss Contingency, Name of Plaintiff									Frank Finazzo

Quarterly Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Quarterly Financial Data [Abstract]
Net sales	$ 3,165,725	$ 2,840,146	$ 1,684,399	$ 2,428,871	$ 2,668,941	$ 2,508,767	$ 2,447,827	$ 2,360,268	$ 10,119,141	$ 9,985,803	$ 9,417,603
Gross profit	859,711	754,299	454,294	746,039	810,598	761,167	767,431	751,690	2,814,343	3,090,886	2,910,747
Restructuring costs	4,380	6,992	15,934	4,787	(1,059)	(802)	11,925	4,641	32,093	14,705	54,367
Operating Income (Loss)	181,200	187,671	(7,433)	173,865	196,334	187,198	162,288	172,441	535,303	718,261	600,619
Net gain on sale of equity investments	1,572	0	0	0	186,769	0	0	0	1,572	186,769	0
Net income (loss) from continuing operations	146,629	151,813	(13,852)	133,847	337,192	143,212	121,417	123,640	418,437	725,461	450,441
Amounts attributable to Henry Schein, Inc. from continuing operations:
Net income	$ 141,921	$ 141,726	$ (11,382)	$ 130,543	$ 330,609	$ 134,916	$ 116,753	$ 118,413	$ 402,808	$ 700,691	$ 430,717
Earnings per share attributable to Henry Schein, Inc. from continuing operations:
Basic (in dollars per share)	$ 1.00	$ 1.00	$ (0.08)	$ 0.91	$ 2.27	$ 0.92	$ 0.79	$ 0.79	$ 2.83	$ 4.70	$ 3.51
Diluted (in dollars per share)	$ 0.99	$ 0.99	$ (0.08)	$ 0.91	$ 2.25	$ 0.91	$ 0.78	$ 0.78	$ 2.82	$ 4.65	$ 3.49

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 26, 2020	Sep. 29, 2018	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Supplemental Cash Flow Information [Abstract]
Interest			$ 43,123	$ 54,685	$ 69,371
Income taxes			206,796	177,277	236,479
Unrealized gain (loss) from foreign currency hedging activities			$ (10,224)	$ (4,911)	$ 1,022
Henry Schein One, LLC. [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Deferred additional ownership interest		$ 160,600
Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Noncash or Part Noncash Acquisition, Interest Acquired	27.00%
Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Business Acquisition, non-cash transaction		$ 390,300
Internet Brands Inc [Member] \| Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Noncash or Part Noncash Acquisition, Interest Acquired		26.00%
Achievement of certain operating targets [Member] \| Henry Schein One, LLC. [Member] \| Henry Schein One, LLC. [Member] \| Internet Brands Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Noncash or Part Noncash Acquisition, Interest Acquired			9.20%

Related Party Transactions (Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
	Jul. 01, 2018	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Related Party Transaction [Line Items]
Due from Related Parties		$ 36.4	$ 31.0
Due to Related Parties		8.6	4.9
Covetrus, Inc. [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		13.0	17.5
Revenue from Related Parties		75.3	81.3
Due to Related Parties		0.3
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party		$ 4.7	9.4
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction		In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $31.0 million annually for the use of their intellectual property.
Related Party Transaction, Expenses from Transactions with Related Party		$ 31.0	31.0	$ 15.5
Related party royalty agreement terms description	ten-year royalty agreement
Internet Brands Inc [Member] \| Scenario, Plan [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 31.0
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction		During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Related Party Transaction, Purchases from Related Party		$ 12.6	11.8	10.8
Revenue from Related Parties		$ 59.6	$ 93.2	$ 27.0

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance For Doubtful Accounts And Other [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 60,002	$ 53,121	$ 46,261
Charged to statement of income	35,137	12,612	14,384
Charged (credited) to other accounts	730	134	(1,158)
Deductions	(7,839)	(5,865)	(6,366)
Balance at end of period	$ 88,030	$ 60,002	$ 53,121